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ABSTRACT 
 
Oncoplastic surgery is considered the standard of care for breast cancer 
therapy in numerous Western World countries, particularly in Europe. Despite the 
advancement of knowledge, Canada still lags in adoption of oncoplasty into the 
standard surgical practice. In our study, a mentorship program was used to 
introduce oncoplastic surgery to practicing breast surgeons at LHSC. The 
change in perception and adoption of oncoplastic surgery were evaluated using 
semi-structured interviews, before and after the intervention, by qualitative 
thematic analysis method. Mentorship program was validated as a superior 
method of learning new surgical techniques by practicing surgeons, 
demonstrating acceptance of different levels of oncoplastic surgery. Identified 
barriers to acceptance included surgeon satisfaction with their initial work, lack of 
formal training, limited availability of courses, and the limitations within the 
Canadian healthcare system. Mentorship program was found to be a valid, 
accessible method for adopting new surgical techniques and needs. As a result, 
oncoplastic surgery started to be adopted at LHSC, providing an example of how 
to facilitate the adoption to other surgical communities. 
 
 
Keywords: oncoplasty; breast cancer; knowledge translation; mentorship; 
surgeon training; 
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CHAPTER 1: GENERAL INTRODUCTION AND LITERATURE REVIEW 
 
 
1.1 BREAST CANCER 
Breast cancer is the most common non-cutaneous cancer diagnosis for 
women in Canada, with approximately 26,300 Canadian women and 230 
Canadian men diagnosed in 2017, and almost 5,000 women and 43 men dying 
of the disease (CanadianBreastCancerFoundation 2017). One out of every eight 
women will develop breast cancer in their lifetime (Canadian Breast Cancer 
Foundation 2017). 
Cancer development is a complex process that is thought to occur as a 
result of an interaction between an environmental factor(s) and a genetically 
susceptible host (Fearon 1997, Tomasetti and Vogelstein 2015). Cell division is a 
physiological process that occurs in most tissue types in the body. In order to 
maintain tissue and organ integrity, the highest degree of regulation of cell 
division must be occur to achieve the proper balance between proliferation and 
programmed cell death (typically occurring in the form of apoptosis). Any 
imbalance in this process, by mutation of the genes responsible for the control of 
either of these processes, can lead to cancer. Cancer cells, therefore, behave as 
cells that have lost the control over their cell replication and tissue growth. As a 
result, they gain the ability to invade into surrounding tissues and spread to other 
areas of the body, ultimately interfering with organ function. This can lead to 
death if not treated or removed. 
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The primary cause of any cancer is thought to be irreparable DNA damage. 
While normal damage to DNA is common (e.g. errors in replication, exposure to 
damaging ionizing radiation), cells contain inherent repair machinery that is 
designed to detect and subsequently fix mutations. If, however, there is some 
form of deficiency in the DNA repair mechanism, more and more DNA damage 
accumulates, thus increasing the risk of cancer. There are two main types of 
genes that are responsible for regulation of cancerous cell growth and 
differentiation: oncogenes – genes normally responsible for regulation of cellular 
growth that have become mutated, resulting in constitutive activation (such that 
protein products are present in inappropriately high numbers, or altered proteins 
that now exhibit new tumour-promoting properties), and tumour suppressor 
genes – mutated genes that normally inhibit cell division or survival of cancer 
cells, but in their absence, the cells suffer a loss of function, which can lead to 
the development of cancer (Fearon 1997, Tomasetti and Vogelstein 2015). 
 
1.1.1 Brief Historical Review of Breast Cancer Treatment 
Breast cancer is an extremely old disease, which has been recorded in 
texts since the ancient times. Breast cancer had been described in the writings of 
that era more than any other form of cancer (Sakorafas and Safioleas 2009). 
The first account of breast cancer comes from the Edwin Smith papyrus of 
the ancient Egyptians, written more than three thousand years ago (about 1600 
BC). The papyrus reported five cases in which a ‘fire drill’ was used to treat 
breast tumours by cauterization (Ekmektzoglou, Xanthos et al. 2009). In the pre-
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Christian era, however, surgery was rarely used as a treatment option, since it 
was believed that only a divine intervention from God could cure the disease 
(Sakorafas and Safioleas 2009). 
The first detailed description of breast cancer originated from Hippocrates 
(460-377 BC). Hippocrates differentiated it from a benign tumour and, based on 
its appearance of a “crab with a center and extending legs”, named it ‘carcinoma’ 
(Ekmektzoglou, Xanthos et al. 2009, Sakorafas and Safioleas 2009). He claimed 
that surgical removal was good for ulcerating tumours, but not for hidden or silent 
ones, as surgery in those cases would only lead to the patient dying sooner. In 
line with the beliefs of his era, Hippocrates attributed the development of a 
cancer to an increase in the level of ‘black bile’ in the body, believing that it 
happened more often in older women, due to the cessation of the menstrual 
cycle. Thus, he introduced the concept of breast cancer as being a systemic 
disease (Ekmektzoglou, Xanthos et al. 2009, Sakorafas and Safioleas 2009). 
Several centuries later, Galen (131-203 AD) further expanded upon 
Hippocrates’ theory that breast cancer occurs as a result of black bile 
accumulation. Galen recommended that breast cancer be treated with purging 
techniques followed by surgical removal. He was the first to discuss disease 
margins, and how they could be damaged by cauterization (Cotlar, Dubose et al. 
2003). 
It wasn’t until the 18th century that early stage of breast cancer began to 
be considered a localized disease, with surgery offered as an effective treatment. 
Henri François Le Dran (1685-1773) suggested that, in addition to excision of the 
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breast tumour, in any cases where the disease had progressed beyond the 
breast, the lymph nodes should also be resected, with the thought that this would 
reduce the likelihood of the disease progressing further to other areas of the 
body (Sakorafas and Safioleas 2010). 
The first proper description of a surgical mastectomy came from Jean-
Louis Petit (1674-1750), a Fellow of the Royal Society of London, and the 
founding director of the Académie Français de Chirurgie (Sakorafas and 
Safioleas 2010). Petit described the details of the ablative cancer surgery which 
included the removal of the breast, removal of any palpable axillary lymph node 
and excision of the pectoralis fascia and muscle as required, to fully remove all of 
the disease. Although not clear how this might have been helpful, Petit used to 
leave most of the skin and the nipple intact, with the notion that it could aid with 
hemostasis, as long as the tissue was not affected by the disease process. 
It was Charles Hewitt Moore (1821-1870) of London who reported that a 
non-enlarged lymph node could still carry the disease, and described that the 
cancer recurrence always occurred in the skin (not the node). He advised that a 
complete axillary dissection should be carried out in breast cancer patients, and 
that as much skin as possible should also be removed (Cotlar, Dubose et al. 
2003). 
William Stewart Halsted (1852-1922) also described the surgical treatment 
of breast cancer as involving removal of the breast, axillary lymph nodes, and as 
much skin as possible, including the pectoralis fascia and muscle. He termed it a 
‘radical mastectomy’. His en bloc resection included the breast with its skin, 
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axillary lymph nodes, pectoralis fascia and the muscle (or at least a part of it), 
through a tear-drop incision. Halsted would leave the wound open, to heal by 
secondary intention (Ekmektzoglou, Xanthos et al. 2009). In his 1894 publication, 
Halsted described 50 cases of breast cancer treated by the radical mastectomy 
approach at Johns Hopkins University, demonstrating that this resulted in a 
breast cancer recurrence rate of 6% – significantly better than other approaches 
that had been previously reported (i.e. 50-80% recurrence rate) (Sakorafas and 
Safioleas 2010). 
The advent of radiation therapy brought a big change in the therapeutic 
approach to breast cancer. George Edward Pfahler (1874-1957) introduced 
routine post-operative radiation to improve the 5-year survival in stage II breast 
cancer (Ekmektzoglou, Xanthos et al. 2009). Robert McWhirter further 
transformed clinical care by reporting that a simple mastectomy (breast and skin 
only) coupled with post-operative regional radiation would yield 5-year survival 
rate of 62%, results similar to those achieved by radical mastectomy (Cotlar, 
Dubose et al. 2003, Ekmektzoglou, Xanthos et al. 2009). David Patey (1899-
1977) standardize the modified radical mastectomy (removal of breast and 
overlying skin with axillary lymph nodes), preserving the pectoralis major muscle 
unless it was also involved (Ekmektzoglou, Xanthos et al. 2009). 
The next advancement in breast cancer therapy came from George Crile, 
Jr., of the Cleveland Clinic. Crile was an early proponent of breast conservation. 
In his 1971 publication, he reported on 57 patients with operable stage I/II breast 
cancer that had undergone local excision of the tumour without axillary dissection 
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or post-operative radiation. He found that the 67% 5-year survival was almost 
identical to that of over 300 patients that had been treated with simple or 
modified mastectomy (with or without radiation). Based on his findings, a 
randomized control trial was designed to compare the outcomes of mastectomy 
versus the new breast conserving surgery. The results demonstrated an 
important difference between stage I and stage II outcomes: while the 10-year 
survival rates were similar between the two surgical approaches, the prognosis 
was worse for patients who had stage II breast cancer (Crile 1971, Ekmektzoglou, 
Xanthos et al. 2009). 
This, as well as many subsequent trials that followed and supported the 
findings (many conducted by the National Surgical Adjuvant Breast and Bowel 
Project (NSABP)), led to breast-conserving surgery being recommended as the 
standard of care the treatment of early stage I/II breast cancer by the National 
Cancer Institute (Ekmektzoglou, Xanthos et al. 2009). 
 
1.1.2 Anatomy of the Breast 
The breast is a paired structure located on the anterior thoracic wall, 
overlaying the pectoral region. Breasts are present in both males and females, 
although they are more developed in females following puberty. In females, the 
breast is composed of mammary glands (the key structures involved in the 
production of milk for lactation) surrounded by a connective and structural 
supportive (fibrous) tissue. 
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Mammary glands are thought to be modified sweat glands, as they consist 
of a series of ducts and secretory lobules. Each lobule is made up of many 
alveoli draining into a single lactiferous duct. The ducts then progressively meet 
and drain into 12-20 main ducts behind the areolar complex that then converge 
and drain out the nipple (Figure 1.1). 
Connective tissue is made up of fibrous and fatty components. It functions 
as a support structure, surrounding the mammary glands and ducts. The fibrous 
stroma condenses to form suspensory ligaments (responsible for the fixation of 
the breast to the dermis and underlying pectoral fascia, and separation of the 
secretory lobules). Pectoral fascia lies at the base of the breast, acting as an 
attachment point to the suspensory ligaments. A layer of loose connective tissue, 
the retromammary space (often used in reconstructive plastic surgery), is found 
between the breast and pectoral fascia (Gray 2000). 
The blood supply to the breast is provided medially by the internal thoracic 
artery (an arterial branch of the subclavian artery), while the lateral part receives 
blood supply from the lateral thoracic and thoracoacromial branches (which, in 
turn, are branches of the axillary artery), lateral mammary branches (originating 
from the posterior intercostal arteries), and mammary branch of the anterior 
intercostal artery (Gray 2000). The venous supply corresponds with the arteries, 
draining into the axillary and internal thoracic veins. Innervation to the breast is 
via the anterior and lateral cutaneous branches of the 4th to 6th intercostal 
nerves; these contain both sensory and autonomic nerve fibers. 	 	
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Figure 1.1 Anatomy of the breast. 
  Adapted from Wikimedia Commons 2017. 
(https://commons.wikimedia.org/wiki/File:Breast_anatomy_normal_scheme.png) 	  
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 There are three groups of lymph nodes that serve as the lymphatic 
drainage of the breast: axillary nodes, retrosternal nodes and variable internal 
mammary nodes. Lymphatic drainage of the breast is of great clinical 
importance, as it plays a significant role in the breast cancer metastasis and 
staging. 
	
1.1.3 Types of Breast Cancer 
Breast cancer is a general term that encompasses several types of 
neoplasm arising from breast tissue. The most common one is adenocarcinoma, 
a term for all cancers originating in glandular tissues; this cancers is felt to 
originate from the epithelial cells lining the milk ducts (termed ‘ductal carcinoma’) 
or the terminal duct lobular units (termed ‘lobular carcinoma’). Over 80% of 
breast adenocarcinomas are derived from the epithelial cells lining the ducts 
specifically, thus often referred to as mammary ductal carcinoma. Ductal 
carcinoma in situ (DCIS) is proliferation of cancer cells within the duct itself but 
without invasion through the myoepithelial and basement membrane lining of the 
ducts (considered Stage 0 breast cancer). Invasive ductal carcinoma (IDC) is 
composed of cancer cells that have invaded through the myoepithelial lining of 
the ducts into the surrounding stromal tissue of the breast. Although DCIS is 
believed to be a non-obligate precursor of IDC, approximately 40% of DCIS will 
progress to IDC if left untreated, evidenced by DCIS and IDC having very similar 
gene expression patterns (Cowell, Weigelt et al. 2013, Harris, Lippman et al. 
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2014). The drivers of invasion, or epithelial-to-mesenchymal transition, remain 
unknown. 
Classic type lobular carcinoma in situ (LCIS) is a marker of increasing risk 
of developing breast cancer in the future (ductal or lobular) in either breast 
(Weigelt, Geyer et al. 2010), although a more aggressive from of LCIS 
(pleomorphic LCIS) is considered a non-invasive lobular carcinoma of the breast 
and is treated the same as DCIS (excision and adjuvant radiation) (Flanagan, 
Rendi et al. 2015). LCIS and its lesser form termed Atypical Lobular Hyperplasia 
(ALH) are relatively uncommon, and are usually an incidental finding in a core 
biopsy that had been indicated for another finding on mammogram. These 
lobular neoplasias are defined by the World Health Organization as “a spectrum 
of atypical epithelial lesions originating in the terminal duct-lobular unit and 
characterized by a proliferation of generally small, non-cohesive cells, with or 
without pagetoid involvement of the terminal ducts” (Harris, Lippman et al. 2014). 
In other words, lobular neoplasms (‘in situ’ or invasive) are characterized by 
neoplastic cells originating in the terminal ductal units, whereas ductal neoplasms 
(‘in situ’ or invasive) are characterized by neoplastic cells originating in the main 
breast ducts. They differ histologically as lobular neoplastic cells do not express 
e-cadherin, whereas ductal neoplastic cells do, and this can be tested by the 
pathologist using immunohistochemistry staining. 
Invasive lobular cancer (ILC), arising from the lobules of the breast, is the 
second most common type of breast pathology. Approximately 10% of all breast 
cancer cases are of ILC type. This is a highly invasive form that can spread 
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through breast tissue and metastasize to other body parts. ILC is usually a 
multifocal disease and is more commonly bilateral than any other type of breast 
cancer (Harris, Lippman et al. 2014). The clinical and radiological presentations 
of ILC are subtle: while LCIS and ILC may present as a palpable mass, the most 
common presentation is a thickening or induration, or what the patient may 
describe as a ‘shrinking of the breast’. ILC is often mammographically occult (not 
visible on screening mammogram), and thus presents as a contour distortion of 
the breast (contracture or elevation of the affected breast compared with the 
other) rather than a palpable discrete mass. 
Medullary cancer is one of the rare breast tumours, accounting for about 
3-5% of all breast cancer. It affects mainly middle-aged women. Although it does 
have an aggressive appearance in the breast primary, it can behave in a less 
aggressive way in terms of propensity for distant metastases (Harris, Lippman et 
al. 2014). Patients usually present with a palpable mass and possible axillary 
lymphadenopathy. Treatment consists of surgery, followed by adjuvant radiation, 
as these tumours tend to be less chemosensitive. 
Papillary cancer accounts for about 1-2% of breast cancer cases, and is 
usually found in older women, who typically present with axillary 
lymphadenopathy, similar to that of medullary cancer. 
Tubular cancer is one of the least aggressive types of breast cancer, and 
it doesn’t usually metastasise outside the breast.  It used to account for less than 
4% of the cases, but with the advancement of screening programs, tubular 
cancer diagnosis is becoming more common. Patients are usually in the later 
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decades of life, and it is rarely seen in men. The majority of patients have an 
abnormal finding on mammogram, with the absence of any clinically palpable 
findings. The mammogram finding tends to be hard to distinguish from IDC, due 
to the speculated margins (Harris, Lippman et al. 2014). The treatment regime for 
tubular cancer is similar to that for IDC. 
Mucinous (or colloid) cancer, as the name suggests, this a tumour 
surrounded by mucus, secreted by the cancer cells. It is considered to be a less 
aggressive type. It is unusual for it to spread to the lymph node. Studies have 
demonstrated that less than 5% of invasive cancer would have some mucinous 
component, with the pure mucinous cancer representing less than half of these 
(Harris, Lippman et al. 2014). Mucinous cancer is usually diagnosed in patients in 
their seventies and eighties. The patients usually present with a palpable mass. 
While the usual treatment is surgical, a controversy exists about the role of 
radiation therapy, considering the benign behaviour of this type of cancer (Harris, 
Lippman et al. 2014). 
Cribriform cancer is a subtype that presents as an invasive carcinoma of 
low-grade, accounting for about 5% of breast cancer cases. The type is well 
differentiated, with features similar to those of tubular cancer. Following surgical 
treatment, cribriform cancer carries a good prognosis (Harris, Lippman et al. 
2014). 
Finally, there are other, less common types of breast cancer. These 
include micropapillary carcinoma, metaplastic carcinoma, carcinoma with 
neuroendocrine features, adenocystic carcinoma, carcinoma with apocrine 
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differentiation, secretory carcinoma, as well as other miscellaneous rare invasive 
breast cancers. The primary management of all breast cancer subtypes is 
surgical excision (Harris, Lippman et al. 2014). 
 
1.1.4 Risk Factors for Developing Breast Cancer 
Many risk factors are associated with the development of breast cancer. 
These include gender (females are more prone than males), age (the risk of 
developing breast cancer increases with age, particularly after menopause), 
reproductive history (risk increases with higher number of ovulatory cycles and 
nulliparity), lactation (lactational changes related to breast feeding reduces risk of 
developing breast cancer), exposure history (ionizing radiation exposure, alcohol 
intake and hormone replacement therapy all increase the risk of having breast 
cancer), height and weight (taller women and those of higher BMI have a higher 
chance of developing breast cancer), family history and Breast Related Cancer 
(BRCA-1/BRCA-2) gene mutation (these significantly increase the chance of 
breast cancer) (Duncan, Reeves et al. 1998, Anand, Kunnumakkara et al. 2008). 
A number of inherited tumour suppressor gene mutations can lead to 
breast cancer, particularly those within the BRCA1 and BRCA2 genes. BRCA 
gene mutations significantly increase the risk of breast cancer development, from 
a 1 in 8 risk for an average woman, to 65-80% lifetime risk for those who are 
BRCA gene mutation carriers (Antoniou, Pharoah et al. 2003).  
Hormones appear to have an important influence over the development, 
progression and recurrence of breast cancer, particularly estrogen and 
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progesterone. These are steroidal sex hormones produced by the ovaries in 
premenopausal women. In postmenopausal women, both hormones are derived 
from the conversion of androgens to estrogen by aromatase in the adrenal 
glands, and (to a lesser degree) in peripheral tissues such as adipose tissue 
(Ryan 1982). Progesterone is derived from pregnenolone, a precursor originating 
from cholesterol (Ryan 1982). Circulating estrogen promotes the upregulation of 
progesterone receptors, particularly in breast tissue (Ryan 1982). Both estrogen 
and progesterone play a role in the female sexual development, maintenance of 
sex characteristics and fertility.  
Two different types of estrogen receptors (ER) have been described: 
alpha (α) and beta (β) (ERα and ERβ, respectively). Various tissues express ER 
(breast, ovaries and the endometrium express ERα, while the kidneys, brain, 
lungs and several other organs express ERβ). The role of ERβ in carcinogenesis 
remains controversial, whereas a clear link between ERα protein and breast 
cancer has been established (Rizza, Barone et al. 2014). Most breast cancers (at 
least 80%) are ER positive and/or PR positive (Ryan 1982). 
A third cell surface receptor is called Her2-neu (transmembrane protein 
from the class of epidermal growth factor receptors) (Hammond, Hayes et al. 
2010). It is present in most tissue types, but can be over-expressed in a number 
of cancers, including breast. It is associated with higher grade and more 
aggressive breast cancers and conveys a worse prognosis. Her2-neu-
overexpressing tumours are treated with chemotherapy in addition to a targeted 
monoclonal antibody treatment called Herceptin, which negates the negative 
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prognosis associated with Her2-neu overexpression, as it significantly reduces 
recurrence and is associated with an improved survival (Rao, Shetty et al. 2013, 
Blanchette, Desautels et al. 2018). 
A number of tumour and patient factors determine the risk of recurrence or 
death from breast cancer (Cianfrocca and Goldstein 2004): tumour stage, 
menopausal status (worse prognosis with pre-menopausal status), tumour grade 
(worse prognosis with higher grade), and tumour phenotype (ER+/PR+/Her2-
neu- are most favourable, followed by ER and/or PR+/Her2+, followed by ER-
/PR-/Her2+ and finally ER-/PR-/Her2- or ‘triple negative’, which carries the worst 
prognosis for survival (Diab, Clark et al. 1999). 
 
1.1.5 Epidemiology 
The total number of diagnosed breast cancer cases progressively 
increased in the 1990s-2000s, but started to decrease after that. This spike is 
most likely due to the improvement in and standardized use of screening 
mammograms, as those assist with the early diagnosis of breast cancer 
(Canadian Cancer Society, 2017). 
Incidence, defined as the number of new cases diagnosed in a population 
over a specified period of time, provides an understanding of the risk of 
developing breast cancer to the general population. Prevalence is the number of 
people living with breast cancer within a population at any give time point. 
Mortality, the number of people that are likely to die from breast cancer in a 
population over a specified period of time, can improve our understanding of the 
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impact that breast cancer has on society, based on the number of lives lost to the 
disease.  
In 2017, it was estimated that 25% of all cancer diagnoses in women were 
those of breast cancer, which makes breast cancer the most common non-
cutaneous malignancy diagnosis for Canadian women. This represented about 
26,300 females in the Canadian population (CanadianBreastCancerFoundation 
2017). The total number of women diagnosed appears to be increasing, most 
likely due to the total population increase (cbcf.org). The incidence of breast 
cancer is known to increase with age, since 83% of breast cancer cases 
diagnosed are in women over the age of 50. Data available from 2009 suggests 
that more than 157,000 Canadian women and over 1,000 Canadian men 
diagnosed with breast cancer since 1999 were still living (cbcf.org), meaning that 
survivorship issues are becoming more and more important (long-term form 
therapy, improved surgical scars and appearance, emotional sequelae from the 
diagnosis and treatment, etc.). 
The last estimated 5-year net survival is about 87% for women, and 79% 
for men (cancer.ca). Approximately 5,000 women, representing 13% of all cancer 
deaths, are anticipated to die this year of metastatic cancer (cancer.ca). 
Breast cancer in young women is known to behave more aggressively, 
leading to a faster progression and a higher cancer-related death. The incidence 
of young onset breast cancer in 2016 was estimated to be around 4,495 
(cbcf.org). Male breast cancer typically has a delayed diagnosis, resulting in a 
more advanced stage at presentation than in females and a lower 5-year survival 
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rate overall. The incidence of Canadian male breast cancer in 2016 was around 
230 (cbcf.org). 
	
1.1.6 Diagnosis of Breast Cancer 
Patients usually present with cancer in one of two ways: a palpable breast 
mass or change in breast appearance, or an abnormality such as a mass or 
microcalcifications seen on screening mammogram. The diagnostic approach 
begins with the appropriate medical imaging for any suspicious finding, with 
mammogram as the first-line gold standard in breast imaging (May L 2014). 
Ultrasound is used to interrogate any area in question on mammogram, as well 
to investigate any palpable concern. Other modalities, including breast magnetic 
resonance imaging (MRI) or contrast-enhanced mammography, are added as 
needed, in order to obtain definitive information regarding the breast tissue and 
whether any area is deemed suspicious and worthy of tissue biopsy for diagnosis. 
Such suspicious results on mammogram or other imaging modality are further 
assessed by an image-guided core needle biopsy. If the clinical finding persists 
but the mammogram and ultrasound are negative, a surgical consultation is 
obtained to determine whether this is an abnormal finding requiring an excisional 
biopsy procedure, or whether further imaging (such as magnetic resonance 
imaging (MRI) if not already done) might be warranted for the few cancers which 
present as mammogram and/or ultrasound occult (May L 2014). 
Once a biopsy is done using image guidance, the specimen is processed 
by the pathology team, using formalin fixation and paraffin embedding for 
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microscopic examination, with hematoxylin and eosin staining. The pathologist 
determines the tissue of origin of the cancer, whether the cancer is in situ or 
invasive, and if invasive, its histologic type and grade. Immunohistochemical 
staining is done to determine whether the cancer cells are ER and/or PR positive 
and whether the cells are HER2 overexpressing (Hammond MEH 2010). If the 
tumour is HER2 equivocal by immunohistochemistry, testing for the HER2 gene 
may be performed by fluorescent in situ hybridization (FISH), to determine 
whether or not the HER2 gene is amplified. 
 Distant staging investigations (searching for distant metastases using 
imaging tests) are not recommended for early breast cancers; however, as the 
risk of distant metastases rises, then staging investigations are recommended 
prior to any systemic therapies. These standardly include a computerized 
tomography (CT) scan of the chest, abdomen and pelvis, and a full body bone 
scan. Imaging of the brain is not indicated in the absence of symptoms, as the 
yield for detecting metastases is otherwise low (May L 2014). 
	
	
1.2 CLASSIFICATION AND STAGING OF BREAST CANCER 
1.2.1 Classification 
Breast cancers can be classified and substratified using a number of 
clinically relevant features. The purpose of classification is to select the best 
therapy and treatment algorithms, as well as to prognosticate. The major 
classification features include histopathological type, the grade of the tumour, the 
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stage of the tumour, and the molecular (ER/PR/HER2) subtype (a surrogate for 
gene expression profile classification).  
Histopathological classification involves the differentiation between in situ 
and invasive breast cancers, as well as their histologic type and grade. 
Histological features roughly stratify the invasive cancers as either no special 
type (infiltrating ductal) or special type (medullary, mucinous, lobular, tubular, 
cribriform), although there are also other more rare forms (e.g. metaplastic, 
apocrine, adenosquamous, etc.) (Bloom and Richardson 1957). Tumours 
showing mixed ‘no special type’ and ‘special type’ features usually behave and 
are classed as a ‘no special type’ tumour of the same histologic type and grade. 
 Grading focuses on the differentiation of the breast cancer cells compared 
to that of the normal breast cells. As the cell division becomes uncontrolled, 
nuclei become less uniform and cell arrangement more disorganized. The grade 
of an invasive carcinoma is assessed using the Scarff-Bloom-Richardson grading 
system, which involves three criteria: tubule formation (the percentage of tumour 
made up of tubular structures (1 point for >75% tubules; 2 points for 10-75% 
tubules and 3 points for <10% tubules)); nuclear pleomorphism (the degree of 
change in the shape and size of the cells’ nuclei (1 point for small and uniform 
nuclei; 2 points for medium to large nuclei but they remain consistent in shape); 
and 3 points for large and varied nuclei)); and mitotic count (number of cells 
under microscope that are actively dividing (1 point for slow mitotic rate; 2 points 
for medium mitotic rate and 3 points for rapid mitotic rate)) (Elston and Ellis 1991). 
Thus every tumour is graded out of a possible 9 points. This is then further 
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collapsed into a score for grade out of three (grade 1=1-5 points; grade 2=6-7; 
grade 3=8-9 points). These could also be described as well differentiated (low-
grade), moderately differentiated (intermediate-grade) and poorly differentiated 
(high-grade) as the cells progressively lose the features and arrangement of 
normal breast cells. The poorer the differentiation is (or the higher the grade), the 
worse the prognosis for the patient. 
 
1.2.2 Staging 
Staging of breast cancer is based on the extent to which the cancer has 
spread away from the primary site of origin. There are two different staging 
approaches used in breast cancer: the Roman numeral staging system, and the 
tumour, lymph nodes, metastasis (TNM) staging system, developed by the 
American Joint Committee on Cancer (AJCC) (Edge, Byrd et al. 2009). The most 
clinically utilized staging is TNM (Edge, Byrd et al. 2009). Although 
lymphovascular space invasion does not change the stage of cancer, it is usually 
associated with a more aggressive phenotype, where the cells have infiltrated 
into veins or lymphatic channels in the area where the tumour is located. 
According to the NSABP-B04, patients with negative nodes have a better 10-year 
survival in comparison to patients diagnosed with node positive invasive breast 
cancer (Harris, Lippman et al. 2014). Therefore, having a precise staging for 
each patient is critical in guiding treatment decisions and providing accurate 
prognosis. 
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1.2.2.1 Roman Numeral Staging System 
Roman numeral staging involves assigning a number to describe the 
progression of cancer. The following stages are recognized: 
Stage 0: carcinoma in situ. 
Stage I: T1 tumours that are lymph node negative. 
Stage II: tumours up to T2 in size, with up to N1 nodal metastases, or T3 
in size but no nodal metastases. This is the most common stage at diagnosis for 
breast cancer. Distant staging is indicated from this stage forward. 
Stage III: This stage is considered locally advanced. These cancers are all 
lymph node positive (N1-N3) or invading surrounding structures (T4). 
Stage IV: cancer has metastasized to other organs or throughout the body. 
 
1.2.2.2 TNM Staging System 
Tumour: tumour classification (TX, T0, Tis, T1, T2, T3 or T4) depends on 
the cancer site. TX refers to an inability to assess that site; T0 means that no 
primary cancer was found; Tis refers to ductal in situ carcinoma, lobular in situ 
carcinoma or Paget’s disease of the nipple; T1 represents tumours up to 2cm in 
size; T2 represents tumours more than 2cm but less than 5cm; T3 represents 
tumours 5cm or greater; T4 represents tumours invading surrounding structures 
including chest wall, skin, both or infiltrating dermal lymphatics resulting in a 
clinical diagnosis of inflammatory breast cancer.  
Lymph Node: lymph node involvement with cancer (NX, N0, N1, N2 or N3) 
depends on the number and location of the involved lymph nodes, whether 
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axillary lymph nodes, the infra or supraclavicular lymph nodes, or the internal 
mammary lymph nodes are affected. NX designation means the lymph nodes 
have not been assessed; N0 signifies no lymph node metastases; N1 means 1-3 
lymph nodes are involved; N2 means 4-9 nodes are involved and N3 means 10 
or more nodes are involved. Clinically, all nodal basins are examined and any 
biopsy proven nodes are classed based on their location: N1 means palpable but 
mobile axillary nodes; N2 represents matted nodes in the axilla or infraclavicular 
or internal mammary nodes; N3 represents nodes found in the supraclavicular 
nodal basin. 
Metastases: The clinically relevant classification for distant metastases for 
breast cancer are M0 and M1, which refers to distant detectable metastases or 
absence thereof. The most likely areas for breast cancer cells to harbour 
clinically visible or relevant metastases are bone, lung, liver and brain. 		
1.3 THERAPEUTIC APPROACH TO BREAST CANCER 
Treatment of breast cancer is usually multimodal, and requires the 
involvement of many specialties. General approaches to breast cancer treatment 
include surgery, chemotherapy, radiation therapy and hormonal manipulation 
therapy. 
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1.3.1 Surgery 
Surgery is one of the primary lines of therapy for breast cancer. The 
purpose is to remove all of the cancerous tissue (tumour), plus some of the 
normal breast tissue all around the tumour to constitute its margins. The extent of 
surgery is dictated by the staging and the type of tumour, and may include 
lumpectomy (removal of the lump) or mastectomy (removal of the whole breast). 
Most early breast cancers (stage I and II) consist of small primary breast cancers 
easily resectable by lumpectomy – ‘breast conserving surgery’ – whereas stage 
III advanced cancers tend to occupy a larger portion of the breast and, therefore, 
require a mastectomy for successful removal of the entire involved area. 
Standard practice requires the surgeon to establish margins clear of cancer, 
indicating that the cancer has been completely excised. If the removed tissue 
does not have clear margins, further operations to remove more tissue may be 
necessary. Therefore, in an effort to minimize the risk of margin positivity while 
reducing the amount of normal breast tissue that needs to be resected, 
particularly in the later stages, neoadjuvant chemotherapy (systemic cytotoxic 
chemotherapy prior to surgical excision rather than afterwards) may be used to 
downsize the primary tumour to render operable breast cancers amenable to 
breast conserving surgery (Wolmark, Wang et al. 2001). 
For larger breast neoplasms that remain extensive despite neoadjuvant 
chemotherapy, or which consist of separate tumours distributed throughout 
different quadrants of the breast, a mastectomy remains the standard of care. 
This involves removing the glandular breast tissue from the pectoralis fascia, 
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resecting overlying skin and nipple-areolar complex and achieving primary skin 
closure over the chest. 
During the operation, the lymph nodes in the axilla must be sampled or 
removed entirely, in order to stage the patient for regional metastases (N stage). 
Until the early 2000s, the standard of care for staging the axilla involved 
resection of all axillary lymph nodes in the level I and II zones, resulting in 
reduced arm mobility, dysesthaesias of the upper arm and a 10-20% risk of 
permanent lymphoedema of the upper extremity. More recently, the technique of 
sentinel lymph node (SLN) dissection has become popular, as it requires the 
removal of far fewer lymph nodes (i.e. fewer side effects) (George, Quan et al. 
2009, Brackstone, Fletcher et al. 2015). SLN mapping can spare 65-70% of 
patients from having a complete lymph node dissection, for what could turn out to 
be a negative nodal basin, but is indicated for early breast cancers felt clinically 
to be lymph node negative. 
 Patients with Stage IV breast cancer are deemed incurable and, therefore, 
goals of care are shifted to extension of quality of life. As a result, there is great 
debate whether the patient should undergo surgery to remove the primary cancer 
if it has already metastasized, especially if the primary tumour appears to be well 
managed by the systemic therapies being given to control the distant disease. 
 
1.3.2 Chemotherapy 
Systemic chemotherapy can be delivered in two main regimens: 
neoadjuvant (prior to surgery) and adjuvant (following surgery). Multiple 
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chemotherapeutic agents may be used in combination. Determining the 
appropriate regimen depends on the character of the tumour (i.e. its hormonal 
status), lymph node status, and the age/health of the patient. Many regimens 
have been clinically evaluated and found to be efficacious in clinical trials, but for 
the majority of breast cancers, the regimens typically used contain an 
anthracycline and a taxane, as these have demonstrated superior survival to 
regimens not containing these classes of drugs (Brackstone, Fletcher et al. 2015).  
 The most common regimens used to treat breast cancer include AC-T 
(anthracycline and cyclophosphamide IV, q3 weekly x 4 or dose-dense as q2 
weekly x 4) followed by taxane (paclitaxel or docetaxel, either q3 weekly x 4 or q-
weekly x 9-12) and FEC-D (5-fluorouracil, epirubicin and cyclophosphamide IV 
q3 weekly x 3) followed by a taxane (docetaxel IV q3 weekly x 3 cycles, or 
paclitaxel IV qweekly x 12 cycles). 	
1.3.3 Radiation Therapy 
Radiation therapy (RT) is used to reduce the risk of locoregional 
recurrence, and is almost always delivered in the adjuvant setting to the surgical 
field. It is the standard of care for in situ or invasive disease in patients treated by 
breast conservation, for reducing by more than 50% the risk of local recurrence 
in the breast following lumpectomy, or following mastectomy for lymph node 
positive breast cancers (Dayes, Rumble et al. 2015). 
 RT involves the delivery of high-energy X-rays that target the tumour, or 
post-surgery tumour site. It can be delivered in the form of external beam 
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radiotherapy (linear accelerator), or brachytherapy (radiation source is placed 
directly at the treatment site). Given that all tissue types are susceptible to 
radiation damage, the dose of radiation must be strong enough to be cytotoxic to 
proliferating cancer cells, but tolerable by the surrounding normal cells. Therefore, 
the radiation delivery is planned using a CT scan where radiation oncologists and 
physicists calculate dosage to deliver even radiation to the area in question while 
constraining doses to critical structures. Acute and late radiotherapy sequelae 
are then minimized by delivering the treatment over many fractions at a low dose 
per fraction (typically 2-3.4Gy/fraction each day). 
 Despite the benefits of RT in lowering the rate of recurrence, RT carries a 
lot of negative effects on the cosmetic outcome (Whelan, Pignol et al. 2010). Due 
to RT-induced various degree of fibrosis, a distortion of breast shape can occur, 
dramatically worsening the cosmetic result of breast conservation. In addition, 
the retraction of the lumpectomy scar towards chest wall is very common 
following the absorption of the seroma in the cavity following the use of standard 
techniques of lumpectomy, particularly when breast tissue mobilization and 
contouring techniques are not used. 
 Other complications of radiation therapy include (but are not limited to) fat 
necrosis and breast fibrosis, radiation pneumonitis and lung fibrosis, radiation-
induced malignancy, as well as skin and soft tissue changes (Yi, Kim et al. 2009). 
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1.3.4 Hormone Manipulation Therapy 
Systemic hormonal manipulation therapy is recommended for all ER 
and/or PR positive breast cancers where there is a significant risk of distant 
relapse, balanced against the toxicity profile of these agents for each individual 
patient. Current recommendations support the use of a selective estrogen 
receptor modulator for 10 years in premenopausal patients, and an aromatase 
inhibitor for 5 years (Brackstone, Fletcher et al. 2015). Thus, the choice of 
hormone manipulation therapy depends on the menopausal status of the patient, 
as well as the response of the patient to treatment. 
Selective estrogen receptor modulator is usually employed as a first-line 
hormonal manipulation therapy in the premenopausal women. An example of this 
type of medication is Tamoxifen, administered once a day for 5-10 years. 
Aromatase inhibitor is employed as a first-line hormonal manipulation 
therapy in post-menopausal women, in patients who failed the first-line 
Tamoxifen, or instead of surgery for elderly patients with non-operable/metastatic 
breast cancer. For example, Letrozole is administered once a day for 5 years. 
 	
1.4 ONCOPLASTIC SURGERY 
Oncoplastic surgery is a form of breast cancer surgery that combines the 
techniques for lumpectomy with those of plastic surgery, to achieve defect 
closure (Urban, Lima et al. 2011, Rassu, Serventi et al. 2013, Santos, Urban et 
al. 2015). By combining the techniques of tumour removal with those used in 
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plastic and reconstructive surgery, it allows for the maximum preservation of the 
appearance of the breast, all without compromising therapeutic outcome.  
In the past, the primary goal of any breast cancer surgery was a 
satisfactory oncological outcome; cosmesis was not regarded as important. 
However, studies have shown that many patients perceive their scar as a very 
negative outcome after several years of survivorship. Up to 30% of women 
surveyed have reported being unhappy or unsatisfied with their cosmetic result, 
significantly worsening their quality of life (Veronesi, Banfi et al. 1990, Driul, 
Bernardi et al. 2013). 
Self-esteem, confidence, social interactions, sexual and emotional 
relations all affect a woman’s self-image. Therefore, it was identified as very 
important to find a reasonable alternative to breast cancer surgery that would not 
only be oncologically safe, but also improve the self-image of the patients after 
the surgery. This gave rise to the field of oncoplastic surgery: a multi-disciplinary 
approach between general and plastic surgeons that offers a breast conserving 
surgery (BCS) techniques in conjunction with chemotherapy and radiation 
therapy, optimizing the rate of breast conservation with much improved cosmetic 
outcomes and patient satisfaction. 
The history of oncoplastic surgery is difficult to trace, as it has not been 
extensively documented. Although the term ‘oncoplastic surgery’ was originally 
proposed by Werner Audrescht in Germany in the 1990s (Audretsch, Rezai et al. 
1998), several sources indicate that the combination of BCS and plastic surgery 
techniques had already been in use well before, in the 1980s, in France (Urban, 
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Lima et al. 2011). Nowadays, the oncoplastic surgery has expanded well beyond 
the almost-exclusive use by the European surgeons. Currently it is employed as 
a standard practice for breast cancer surgery in Europe and some places in the 
United States, North America, Australia, and is just beginning in Canada. 
 
1.4.1 Indications for Oncoplastic Surgery 
Oncoplastic surgery offers a solution for patients who would not be good 
candidates for BCS for a variety of reasons, including the presence of large 
lesions, tumours that are not chemo-sensitive (e.g. ILC, DCIS), size and location 
of the tumour, particularly those in the upper inner quadrant or around the 6 
o’clock position, and multifocal/multicentric tumours (Cil and Cordeiro 2016). 
Oncoplastic surgery offers many advantages, particularly in the adjuvant 
radiotherapy setting: less exposure of the breast tissue to radiation, hence fewer 
complications attributable to radiation (Munhoz, Montag et al. 2013). For example, 
in their clinical series, Gray et al (1991) found that patients with larger breast and 
more fatty tissue are more prone to radiotherapy complications, particularly 
retraction, symmetry issues and necrosis (Gray, McCormick et al. 1991). 
 
 
1.5 CLASSIFICATION OF ONCOPLASTIC SURGICAL TECHNIQUES 
Several methods can be used to classify oncoplastic surgical techniques 
in order to facilitate a better understanding of the variety of procedures that fall 
under the umbrella of oncoplastic surgery. There are two fundamentally different 
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approaches used to manage breast defects created by lumpectomy surgery: 
volume displacement and volume replacement techniques. Volume displacement 
techniques combine resection of the tumour followed by breast tissue 
rearrangements with mammoplasty, breast reduction and reshaping cosmetic 
techniques, all done as part of the same operation. On the other hand, volume 
replacement procedures combine resection with immediate reconstruction using 
loco-regional flaps with tissues outside the breast. While volume displacement 
methods are good for a D or larger-cup-sized breast, small to medium-sized 
breast derives the maximum benefits from volume replacement techniques 
(Noguchi, Yokoi-Noguchi et al. 2016). 
Volume displacement oncoplastic surgery can be further divided into Level 
1 and Level 2, according to the quantity of breast tissue to be removed, the 
quality of the breast tissue and the tumour location (Clough, Kaufman et al. 2010). 
 Level 1 oncoplastic techniques are used for defect closure and tissue 
undermining when the anticipated volume loss in a glandular breast is less than 
20%, without the need for skin excision or mammoplasty. Level 2 includes 
techniques that are more complex: they are used in fatty breasts, in instances 
where the anticipated resection of the breast volume is 20-50%, and excision of 
the excess skin is required to reshape the breast. The mastery of level 2 
oncoplastic techniques requires specialized training in various mammoplasty 
techniques. 
 
	 32 
1.5.1 Level 1 Oncoplasty 
The techniques, originally described in detail by Clough et al (Clough, 
Kaufman et al. 2010) include general standard steps that can be adapted or 
modified according to necessity in each individual case (Figure 1.2). The main 
aim of the procedure is to close the defect of lumpectomy in such way as to 
eliminate the formation of seroma and avoid resultant contour deformity. 
The surgical procedure begins with a skin incision, followed by 
undermining of the skin and nipple areolar complex to obtain easy mobilization of 
the breast gland itself. Lumpectomy then proceeds as planned. Once the 
excision is completed, the breast gland is mobilized off the pectoralis fascia (dual 
gland mobilization from skin and chest wall) to close the defect. At this stage, 
recentralization of the nipple is performed using de-epithelization, i.e. the removal 
of the skin epidermal layer to plicate the dermis and recentralize the nipple over 
the breast mound. No other skin removal is required, thus the existing dermal 
layer with the dermal plexus and nerves provides the blood supply to the 
mobilized skin of the breast and the nipple. 
 
1.5.2 Level 2 Oncoplasty 
The techniques of mammoplasty utilized in level 2 oncoplastic surgery 
vary (Figure 1.3), depending on the region to which the tumour is localized and in 
which breast quadrant the surgery will be performed. 
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Figure 1.2 Level 1 oncoplastic surgery. The fibroglandular tissue is 
advanced over the pectoralis muscle to separate deeper tissues 
from the overlying skin. (A) lumpectomy, (B) apositioning of 
margins, (C) defect closure. 
Adapted from Oncoplastic Breast Surgery 
(https://plasticsurgerykey.com/oncoplastic-breast-surgery). 
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Figure 1.3 Overview of level 2 oncoplastic surgical reconstruction 
techniques. A quadrant-per-quadrant approach to the choice of 
surgical technique depends on the area of tumour localization. 
 Reproduced with permission from Clough et at (2012). 
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1.5.2.1 Tumours at the Upper Pole (at 12 O’Clock Position) 
For tumours in the upper pole of the breast, i.e. those localized in the 
superior aspect of the breast from 11-1 o’clock based on the lock orientation, two 
most appropriate techniques to be used are the ‘round block’ (Benelli 1990) 
(Figure 1.4) and the inferior pedicle mammoplasty (Robbins 1977) (Figure 1.5). 
Inferior pedicle mammoplasty involves the use of existing breast tissue and its 
blood supply from the lower pole of the breast, to fill in the generated defect in 
the superior pole, as one would do in a cosmetic ‘breast reduction’ or ‘breast lift’. 
 
1.5.2.2 Upper Inner Quadrant 
Tumours in the upper inner quadrant are those localized to 9-11 o’clock 
position of the left breast or 1-3 o’clock position of the right breast. The best 
approach to these is to use the batwing  (Figure 1.6) and the round block (Figure 
1.3) procedures (Anderson, Masetti et al. 2005, Clough, Ihrai et al. 2012). 
 
1.5.2.3  Upper Outer Quadrant 
For the tumours localized to the upper outer quadrant, i.e. at 1-3 o’clock in 
the left breast and 9-11 o’clock in the right breast, lateral or raquet mammoplasty 
is the most suitable technique (Ballester, Berry et al. 2009) (Figure 1.7).  The 
procedure consists of the removal of a lateral wedge of breast tissue, including 
the tumour and the overlying skin. Briefly, an incision is made that extends 
laterally from the edge of the nipple areola complex (NAC), as necessary. The 
same incision is then utilized  for  SLN biopsy  (SLNB). Glandular  mobilization  is  
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Figure 1.4 Round block mastopexy technique in level 2 oncoplastic 
surgery. (A) Preoperative design with two circular skin markings, 
(B) lumpectomy and de-epithelization,  (C) undermining and 
approximation of nearby breast tissue, (D) postoperative periareolar 
scar. 
 Adapted from Yang et at (2012). 
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Figure 1.5 Inferior pedicle mammoplasty in level 2 oncoplastic surgery. 
The existing breast tissue and its blood supply from the lower pole 
of the breast is used to fill in the generated defect 
 Adapted from Clough et at (2010). 
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Figure 1.6 Batwing mastopexy in level 2 oncoplastic surgery. Batwing 
mastopexy. (A) Preoperative design with batwing form, (B) 
lumpectomy, (C) pulling up the inferior breast tissue. 
 Adapted from Yang et at (2012). 
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Figure 1.7 Lateral mammoplasty (‘tennis racket’) in level 2 oncoplastic 
surgery. (A) Preoperative design with racket form, (B) lumpectomy 
and de-epithelization, (C) filling and nipple-areolar complex 
reposition. 
 Adapted from Yang et at (2012). 
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then carried out at the level of pectoralis major muscle. The remaining lateral and 
central glandular tissue is mobilized while keeping the skin attached to the 
glands; this is then used to fill the defect while preserving a good blood supply to 
the tissue. Complete detachment of NAC from the underlying tissue assists with 
mobilization of the central glandular tissue for volume replacement at the 
lumpectomy defect (Clough, Ihrai et al. 2012). Once the defect is closed, re-
centralization of the nipple is carried out by de-epithelization of the crescent of 
skin medial to NAC. 
 
1.5.2.4 Tumours at the Lower Pole (at 6 O’Clock Position) 
For the tumours localized to the lower pole of the breast, i.e. those at 5-7 
o’clock position, superior pedicle mammoplasty offers the most appropriate 
approach. The technique employs an inverted T-shaped skin incision. The 
procedure begins by marking the superior pedicle and the tumour, followed by 
de-epithelization of the pedicle. An incision is made at the infra-mammary fold 
(IMF), and a wide dissection at the level of pectoralis major is carried out. 
Ensuring a wide clinical margin around the tumour, the lower pole tissue and 
some of the central tissue are all removed en bloc. Lateral and medial tissues are 
re-approximated, and sutured to the IMF. During the final stage of the procedure, 
the nipple is recentralized over the new breast mound (Clough, Ihrai et al. 2012). 
This technique is also commonly used for ‘breast reduction’ or ‘breast lift’ 
procedures, where up to 60% of the breast volume can be resected, providing an 
oncologically sound breast conserving surgery while recreating a smaller, but 
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rounder and more aesthetically pleasing breast mound, that is usually 
cosmetically better after surgery than before. 
 
1.5.2.5 Lower Inner Quadrant 
For tumours of the lower inner quadrant, i.e. those localized to 7-9 o’clock 
position in the left breast and 3-5 o’clock position in the right breast, V 
mammoplasty (Figure 1.8) is the best option (Clough, Ihrai et al. 2012). The 
technique involves making a V-shaped incision over the tumour, with the apex 
pointing towards the margin of the areola, carrying out the dissection to the level 
of pectoralis major. Following tumour excision, another incision is made at the 
level of the IMF, extending to the anterior axillary line. Breast tissue is dissected 
at the level of pectoralis major, and the entire inferolateral breast tissue is 
mobilized medially to fill the defect, suturing it to the medial breast tissue. 
Following this, the skin around the NAC is de-epithelized and the NAC is then 
positioned over the superomedial pedicle. 
Although more appropriate for the lower pole tumours, superior pedicle 
with inverted T-shape incision is another technique that may be, in some cases, 
useful on tumours of the lower inner quadrant (Clough, Ihrai et al. 2012). 
 
1.5.2.6 Lower Outer Quadrant 
Tumours of the lower outer quadrant are those localized to 3-5 o’clock 
position in the left breast and 7-9 o’clock position in the right breast. For these, J 
mammoplasty (Figure 1.9) is the best option. In this technique, the vascularity of   
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Figure 1.8 V mammoplasty technique in level 2 oncoplastic surgery. (A) 
V-shaped incision, (B) lumpectomy, (C) inferolateral tissue 
mobilization, (D) scar. 
 Adapted from Clough et at (2010). 
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Figure 1.9 J mammoplasty technique in level 2 oncoplastic surgery. (A) J-
shaped, oblique incisions from both sides of NAC, (B) lumpectomy, 
(C) lateral, medial and central glandular tissue are pulled together 
to achieve defect closure. 
 Adapted from Clough et at (2010). 
  
A B C 
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the NAC is primarily dependent on the de-epithelized superior pedicle. The 
procedure begins by making an oblique incision originating at the edge of de-
epithelized skin and extending towards the IMF. Another, similar incision is made 
from the other side of de-epithelized skin edge, directed towards  the  IMF,  to  
meet  the  end  of  the  first  incision.  Glandular dissection follows the pattern of 
skin incision. The defect is closed by complete separation of the NAC from the 
underlying glandular tissue; the lateral, medial and central glandular tissue are 
then pulled together to fill the defect and to reshape the breast (Clough, Ihrai et al. 
2012). 
 
1.5.3 Level 3 Oncoplasty 
Classification of oncoplasty can be further enhanced to incorporate Level 
3 procedures. Level 3 oncoplasty techniques are utilized to perform the reduction 
mammoplasty that is coupled with the contralateral breast symmetrization. Level 
3 oncoplastic surgical procedures are carried out in tandem with the plastic 
surgery team, particularly when the balancing procedures are planned. Level 3 
oncoplasty requires additional plastic surgery training to properly balance these 
techniques and the contralateral cosmetic balancing component. 
Surgical procedures employed include the use of wise pattern reduction 
(Figure 1.10), vertical mammoplasty (Figure 1.11) and J/V mammoplasty 
techniques (Figures 1.8 and 1.9). Depending on the tumour position, wise pattern 
reduction uses the superior, superomedial or inferior pedicle, and results in an 
anchor-shaped scar. For the tumours in the lower pole, the most optimal choice 	  
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SUPERIORLY BASED PEDICLE 
 
 
 
 
 
 
 
Figure 1.10 Wise pattern reduction in level 3 oncoplastic surgery. Wise 
pattern (inverted T) reduction with inferiorly based (top row) or 
superiorly based (bottom row) pedicle. (A) Preoperative design, (B) 
lumpectomy and de-epithelized pedicle elevation, (C) transposition 
of the pedicle into the new location. 
Adapted from Yang et at (2012).  
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Figure 1.11 Vertical mammoplasty in level 3 oncoplastic surgery. (A) 
Preoperative design, (B) Lumpectomy and de-epithelized pedicle 
elevation, (C) new nipple positioning. 
Adapted from Yang et at (2012). 
	 	
	 47 
of technique is vertical mammoplasty, which uses the superior pedicle to 
maintain the blood supply to the nipple. 
 
 
1.6 OUTCOMES OF ONCOPLASTIC SURGERY 
In general, the outcomes of oncoplastic surgery appear very favourable. 
The main aspects that always must be considered are oncological safety, 
cosmetic outcome and patient satisfaction (Noguchi, Yokoi-Noguchi et al. 2016). 
 
1.6.1 Therapeutic Outcome 
As with any cancer surgery, the most important outcome is the complete 
removal of malignancy together with a maximally safe oncological margin to 
minimize the risk of recurrence. In breast cancer surgery, particular attention 
must be paid to invasive tumours, ensuring that there remain no cancer cells at 
the margin of the lumpectomy specimen. In DCIS, the goal is to remove the 
complete area of involved ducts plus a 2mm margin of normal tissue in all 
directions within the lumpectomy specimen, again to minimize the risk of local 
recurrence. During a standard lumpectomy, glandular resection of surrounding 
normal tissue is minimized in order to diminish the amount of volume loss and 
asymmetry, given that cosmesis is directly related to the volume of tissue 
resected. However, with this oncoplastic approach, glandular tissue can be 
excised widely around the tumour while reshaping the breast without 
compromising the cosmetic outcome. This not only ensures a clear margin, but 
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also provides the patient with a nice breast shape (Ho, Stallard et al. 2016). 
Ensuring wide margins at the time of the oncoplastic lumpectomy reduces the 
likelihood that the margins are positive, thus reducing the need for further 
surgeries to resect more and achieve a clear margin. 
Cosmetic results have been proven to be superior following oncoplastic 
surgery when compared to standard lumpectomy techniques (Veronesi, Banfi et 
al. 1990). Reshaping of the breast according to the tumour position and the 
nature of the breast tissue yields a round, smaller breast that is more youthful 
and aesthetically pleasing. As such, the patient satisfaction is significantly 
improved over standard techniques (Noguchi, Yokoi-Noguchi et al. 2016). 
 
1.6.2 Risks and Complications 
As with any other surgical technique, oncoplastic surgery also carries risks 
and a range of complications, as reported in the literature. The reported overall 
rate of complications in oncoplastic surgery has been reported to be 16%, versus 
those of 20% in BCS (Losken, Dugal et al. 2014). Therefore, although more 
involved technically, oncoplastic surgery is not associated with a significantly 
worsened complication rate. 
Oncoplastic surgical complications are generally divided into early and late 
(Munhoz, Montag et al. 2013). The early complications include wound healing 
problems and post-operative bleeding among others (Cil and Cordeiro 2016),  
posing a potential delay to the administration of adjuvant therapy, although it 
does not appear that oncoplastic surgery results in a clinically meaningful delay 
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for any adjuvant therapy (Munhoz, Montag et al. 2013). Although requiring 
additional operative time and more tissue resection, oncoplastic surgery has not 
resulted in any changes in the rate of early complications (Cil and Cordeiro 2016). 
The risk of a positive margin after resection must be considered: while 
uncommon considering the wider excision margin and larger specimen, some 
risk is always present (Piper, Peled et al. 2015). Thus, the surgeon must decide 
whether the tumour bed can be properly identified, and how much mobilization 
needs to be carried out, not discounting the possible need for future re-excision. 
If during the first surgery, significant tissue advancement and mobilization was 
required, the difficulty in taking all of this apart and finding the original tumour bed 
during a second operation in order to perform a re-excision for margins is high. 
As such, a completion mastectomy would be the appropriate option to consider in 
these cases. Therefore, one can appreciate the importance of a detailed 
operative report describing all the specifics of the procedure in a step-wise, clear 
and concise manner, facilitating margin re-excision if required as a second 
surgery. 
Fat necrosis (ischemia of the fatty tissue in the breast) is a surgical 
complication that must always be considered, particularly in breast surgical 
procedures requiring significant amounts of tissue undermining, mobilization and 
with potentially tenuous blood supply (Munhoz, Montag et al. 2013). As with any 
surgical procedure, a full grasp of the anatomy and blood supply is crucial for a 
successful outcome. The quality of the breast tissue has to be considered on a 
case-by-case basis, prior to making any decision regarding surgery: fatty 
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replaced breast tissue carries a higher risk of infection and fat necrosis when 
mobilized at two levels. The risk of nipple ischemia and resultant nipple loss 
depends on the amount of vascular compromise, making the preservation of 
appropriate vascularity to the nipple crucial to the planning process. Some loss of 
nipple sensation is always expected, particularly if a complete nipple undermining 
is carried out. 
Asymmetry is an issue that must be addressed with the patient ahead of 
time. Some surgeons prefer to offer the patient a concurrent symmetrization of 
the contralateral side if the patient requires a level 2 or 3 oncoplastic procedure, 
but this needs to be discussed well ahead of the surgical date if the best outcome 
is to be achieved. In addition, the need for post-surgical radiation therapy has to 
be considered, as an extra volume of 15-20% of normal breast tissue must be 
preserved on the affected side (in comparison to the healthy side) to compensate 
for radiation-induced fibrosis and volume loss. 
Proper identification of the tumour bed (the location where the tumour was 
originally situated, representing the area at highest risk for local recurrence and 
therefore the area requiring adjuvant radiation the most) remains a great 
challenge in oncoplastic surgery, constituting a major problem for patients 
needing a boost of additional radiation treatment to the tumour bed specifically 
for higher risk tumours (Munhoz, Montag et al. 2013). To address this issue, 
several solutions have been proposed. First, multiple use of titanium clips on the 
original tumour bed prior to tissue mobilization has been recommended, advising 
the placement of at least four clips on the pectoralis overlying the chest wall. 
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Second, intra-operative radiation treatment has been suggested, where a pre-
calculated dose is delivered to the lumpectomy cavity prior to tissue mobilization 
(Silverstein, Mai et al. 2014); it is widely available in Canada. Following this, the 
oncoplastic mobilization can then be completed. 
 
1.7 THESIS RATIONALE 
Oncoplastic surgery is considered a standard of care in breast cancer, 
particularly in developed countries, such as in Europe, the United States and 
South America, as well as Australia. Unfortunately, Canada lags behind in the 
routine use of these techniques. One of the major barriers to the uptake of 
oncoplasty is the necessity of very specialized training in the use and methods of 
oncoplastic surgical techniques. While some hands-on training is offered through 
specific oncoplastic surgery courses, particularly in European countries, the 
workshops are expensive, time-consuming (the surgeon must travel to the 
destination) and take time away from patient care. The purpose of this thesis is to 
evaluate dissemination of specialized knowledge such as oncoplastic surgery, 
using intra-operative mentorship as a method, to enhance the adoption of novel 
surgical techniques. 
 
1.7.1 Thesis Outline 
This thesis monograph describes on the practice of oncoplastic surgery as 
a therapeutic option for patients with breast cancer. The purpose of the study 
was to evaluate a strategy of intra-operative mentoring as a method of 
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influencing the current surgical practice into adopting the novel oncoplastic 
surgical techniques.  
In Chapter 1, breast cancer is introduced and summarized; epidemiology, 
diagnostics, current therapeutic options and outcomes are reviewed. Oncoplastic 
surgery is introduced, providing some technical details of this surgical method, 
indications, outcomes and complications.  
In Chapter 2, the qualitative method of data analysis and evaluation are 
introduced. For the purpose of this study, intra-operative mentoring as a means 
of knowledge translation was chosen to assist with the dissemination of technical 
knowledge to breast surgeons already in practice, with the aim of initiating or 
improving the adoption of oncoplastic surgery into standard practice. The details 
of this intervention, the intra-operative mentorship of practicing breast cancer 
surgeons at the University of Western Ontario by an oncoplastic surgery-trained 
breast surgeon, as well as the pre- and post- intervention evaluations through 
semi-structured interviews with qualitative thematic analysis are also described. 
In Chapter 3, the results of this mentorship trial are detailed. Study 
limitations and barriers to adoption of these complex techniques are also 
summarized. 
Finally, Chapter 4 discusses the outcomes of this intervention, in terms of 
knowledge dissemination, as well as implications for the adoption of new and 
complex techniques into an existing surgical repertoire. Study limitations and 
barriers to adoption of these complex techniques are further expanded. Future 
directions for this project are also provided. 
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CHAPTER 2: MATERIALS AND METHODS 
 
The study was conducted within the Department of Surgery, Schulich 
School of Medicine at the University of Western Ontario, and at London Health 
Sciences Centre and St. Joseph’s Healthcare Centre, London, ON. The study 
used qualitative research design, and employed Rogers’ diffusion of innovation 
theory (Rogers 1983). 
 
 
2.1 QUALITATIVE RESEARCH 
Qualitative research is a method of inquiry used in many different 
academic disciplines (Denzin and Lincoln 2005). It encompasses a broad 
methodological approach that includes many research methods. While the 
purpose of qualitative research may vary with the disciplinary background, the 
methods examine or interpret phenomena in terms of the meanings that people 
bring to them (Greenhalgh and Taylor 1997). 
 
2.1.1 Overview 
Research in the clinical setting can be broadly divided into two techniques: 
those using quantitative and those using qualitative methods. Quantitative 
methods use measureable numeric data, attempting to answer the questions of 
what in an objective manner. On the other hand, qualitative methods focus on 
how and why aspects, in order to gain deep understanding of the topic by 
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analyzing narratives in a systemic and rigorous process, following the routes of 
standard scientific inquiry (Sim and Wright 2000). 
Qualitative analysis is frequently used to explore new areas that have not 
yet been examined; it broadens the research field to include evaluations that give 
greater insight to both the research question and the data collection, and is 
usually the first step undertaken in understanding a phenomenon (the how and 
why of something) before quantitative research can be carried out. When applied 
properly, qualitative research is a valuable method used to develop theory, 
evaluate programs and design interventions (Baxter and Jack 2008, Choo, Garro 
et al. 2015). 
Qualitative research has its foundation in social sciences, and the 
humanities — from disciplines such as anthropology, sociology, education, and 
history (Lingard and Kennedy 2007). The importation of methods from these 
disciplines into research in the clinical setting began in the 1980s, when more 
prescriptive theory was called for to complement the dominant paradigm of a 
controlled experiment. 
Qualitative methods use an inductive approach to knowledge generation, 
allowing an individual experience to form the basis of understandings of 
phenomenological experiences. In the healthcare setting, qualitative research 
may be used to identify and describe new clinical problems, develop surveys, 
generate standards of care, as well as evaluate an intervention (Lingard and 
Kennedy 2007, Choo, Garro et al. 2015). The main differences between 
qualitative and quantitative methods are summarized in Table 2.1.  
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Table 2.1 Comparison of qualitative and quantitative studies 
  Adapted from Choo et al, 2015. 
 
CHARACTERISTIC QUALITATIVE QUANTITATIVE 
 
Nature of concept 
 
Unfamiliar, poorly defined 
 
Clearly defined 
 
Main goals of the study 
 
Gain in-depth 
understanding 
 
Obtain detailed numerical 
description or functions of 
a representative sample. 
Find generalizable results. 
 
Types of Measurement 
 
Exploratory, formative, 
confirmatory 
 
Structured; hypothesis- 
driven, with intent to test 
hypothesis 
 
Data Collection 
 
Flexible, to allow in-depth 
understanding and 
discovery of the 
unexpected. 
Questions posed to 
participants can be 
modified in the course of 
the study. 
 
Validated; repeatability of 
measure is important. 
Research questions and 
measures decided a priori, 
not subject to change. 
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Table 2.1 Comparison of qualitative and quantitative studies – con’t 
 
 
CHARACTERISTIC QUALITATIVE QUANTITATIVE 
 
Data Collection 
(con’t) 
 
Typically concludes when 
data saturation is met and 
no new information is 
discovered. 
 
Concludes at an 
established sample size. 
 
Data Analysis 
 
Iterative; used to modify 
research questions for 
ongoing study 
 
Constructed a priori; not 
influenced by data 
collection. 
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2.1.2 Types of Qualitative Designs and Research Questions 
Qualitative research design allows multiple methodological approaches to 
be used in order to understand complex situations. Widely used designs include 
narrative research, case study, grounded theory, phenomenology and 
participatory action research (Cresswell 2007) (Table 2.2). 
Key features of a qualitative research study design include the sampling 
framework employed, the data collection methods, types and sources used, and 
the data analysis methods undertaken. Qualitative research designs more often 
than not evolve during data collection and analysis (Devers 1999). Therefore, it is 
critical to remember that it is the research question that drives the research 
approach as well as the data collection methodology. 
Qualitative research has several recognizable characteristics, and is 
frequently done in natural settings, usually as part of an observation or analysis 
of the behaviour of an individual or a group. This observation is then presented 
with a description rich with both detail and insight into the setting (Pope and 
Mays 2000). 
 
2.1.3 Types of Qualitative Data Collection Methods 
Qualitative researchers face many choices for techniques to generate 
data. These range from grounded theory development and practice, narratology, 
storytelling, state/governmental studies, research and service demonstrations, to 
focus groups, case studies, participant observation, qualitative review of statistics 
in order to predict future happenings, or shadowing (Choo, Garro et al. 2015).  
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Table 2.2 Research questions and their qualitative design. 
  Adapted from Cresswel et al, 2007. 
 
TYPE OF RESEARCH QUESTION QUALITATIVE DESIGN 
 
Chronological/story-oriented questions:  
Questions about the life experiences of an individual 
and how they unfold over time 
 
Narrative research 
 
In-depth; descriptive questions:  
Questions about developing an in-depth understanding 
about how different cases provide insight into an issue 
or unique case 
 
Case study 
 
Process questions:  
Questions about experiences over time or changes that 
have stages and phases 
 
Grounded theory 
 
Essence questions:  
Questions about what is at the essence that all people 
experience about phenomenon 
 
Phenomenology 
 
Community action questions: 
Questions about how changes occur in a community 
 
Participatory action 
research 
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Qualitative research is there to explore and develop a hypothesis, 
whereas quantitative research is structured and aims to confirm a hypothesis. 
While quantitative research is inductive, qualitative research is deductive. 
Quantitative research quantifies variations and determines cause and effect with 
closed questions, whereas qualitative research describes variation and group 
norms with open-ended questions. Data within the qualitative method is verbally 
focused while quantitative data is numerically focused. Thus, the study designs 
of the two methods are quite different: within quantitative research, the study 
design is set and does not change, whereas qualitative research allows the 
design to emerge and evolve based on the research findings. 
 
2.1.3.1 Data Collection Models 
The collection methodology is always driven by the research question. 
Sometimes, a number of different techniques are needed to gather enough data 
for a complete picture. Data collection models most often used in qualitative 
research include the interview, focus group, written narratives, observations and 
document reviews (Sullivan and Sargeant 2011).  
The most common method used to generate data is an interview, which 
may be structured, semi-structured or unstructured. During the interview, the 
person’s feelings, thoughts and experiences can be discussed with the 
appropriate questioning or probing by the researcher.  
Group discussions or focus groups offer another way to generate data 
(Savin-Baden and Major 2013). The focus group usually includes about 8-10 
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people from whom information pertinent to the research is elicited; the 
information (including confirmation or clarification) is usually documented and 
coded later. 
Written narratives require the person writing the narrative to critically 
reflect on the circumstances or events being studied. 
Simple observations can also be used to gather data; however, the person 
observing a group needs to be aware of their personal bias so as not to interrupt 
the flow of the group being observed (Savin-Baden and Major 2013). 
Finally, document review can also be used for data gathering. Although 
important, the review of documents does not appear to involve the human quality 
found in most of the other data collection methods. Yet, clearly it is needed in 
some instances, e.g. background information to the research (Savin-Baden and 
Major 2013). 
 
2.1.4 Qualitative Interviewing 
Qualitative data collection that involves interviewing can be broadly 
subdivided into three categories: structured, semi-structured or unstructured (Gill, 
Stewart et al. 2008). Structured interviews are relatively quick and easy to 
administer. Usually, they are verbally administered questionnaires asking a list of 
predetermined questions, with little or no variation, and with no scope for follow-
up questions to responses that warrant further elaboration. Structured interviews 
may be of particular use if clarification of certain questions is required, or if there 
is likely to be literacy or numeracy problem with the respondents. However, their 
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nature only allows for limited participant responses, thus they are of little use if 
'depth' is required (Gill, Stewart et al. 2008). 
Unstructured interviews do not reflect any preconceived theories or ideas. 
They are performed with little or no organization, and very time-consuming (often 
lasting several hours). This makes them difficult to manage and to participate in, 
as the lack of predetermined interview questions provides little guidance on what 
to talk about (which many participants find confusing and unhelpful) (May 1991).  
The interview may start with a simple opening question, and will then progress 
based upon the initial response. Their use is generally only considered where 
significant 'depth' is required, or where virtually nothing is known about the 
subject area (or a different perspective of a known subject area is required) (May 
1991). 
Semi-structured interviews consist of several key questions that help to 
define the areas to be explored. At the same time, they allow the interviewer or 
interviewee to diverge, in order to pursue an idea or response in more detail 
(Pope and Mays 2000). They are usually scheduled in advance at a designated 
time and location, usually taking between 30 minutes to several hours to 
complete, and are only conducted once for an individual or a group. This 
interview format is used most frequently in healthcare, as it provides participants 
with some guidance on what to talk about. The flexibility of this approach allows 
for the collaboration between investigator and participants, and the elaboration of 
information that is important to participants, but may not have previously been 
thought of as ‘pertinent’ by the research team (Gill, Stewart et al. 2008). 
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2.1.5 Thematic Analysis of Qualitative Data 
Thematic analysis, one of the foundational evaluation methods in 
qualitative research, is defined as a technique for identification, analysis and 
reporting of patterns (i.e. themes) within data. The method is characterized by its 
flexibility: it allows the researcher to develop a rich and detailed set of data in 
order to understand the phenomenon in question. This makes it ideal for use in 
new or under-researched areas. The advantages include flexibility, ease of 
learning, ease of access to researchers with little qualitative research experience, 
and the ease of access of the results to general public (Braun and Clarke 2006) 
(Table 2.3). 
Themes are defined as patterns across data sets that are important to the 
description of a phenomenon, and are associated to a specific research question 
(Fereday and Muir-Cochrane 2006). Therefore, the themes become the 
categories for analysis. 
 
2.1.5.1 Steps Undertaken to Perform Thematic Analysis 
Thematic analysis is performed through the process of coding in six 
phases to create established, meaningful patterns: familiarization with data, 
generation of initial codes, search for the themes among codes, review of 
themes, definition and  naming of themes, and production of the final report 
(Braun and Clarke 2006) (Table 2.4). 
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Table 2.3 Advantages of thematic analysis. 
  Adapted from Braun and Clarke 2006. 
 
 
ADVANTAGES 
 
• Flexibility 
• Relatively easy and quick method to learn and do 
• Accessible to researcher with little or no experience of qualitative 
research 
• Results are accessible to educated general public 
• Useful method for working within participatory re-search paradigm, with 
participants and collaborators 
• Can usefully summarize key features of a large body of data, and/or 
offer a ‘thick description’ of the data set 
• Can highlight similarities and differences across the data set 
• Allows for social as well as psychological interpretations of data 
• Can be useful for producing qualitative analyses suited to informing 
policy development 
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Table 2.4 Steps in Thematic Analysis 
  Adapted from Braun and Clarke 2006. 
 
PHASE ACTION DESCRIPTION 
 
Phase 1 
 
Familiarizing oneself 
with one’s data 
 
Transcription of data (if necessary), reading 
and re-reading the data, noting ideas 
 
Phase 2 
 
Generation of initial 
codes 
 
Coding interesting features of the data in a 
systematic fashion across the entire data 
set, collating data relevant to each code 
 
Phase 3 
 
Search for themes 
 
Collating codes into potential themes, 
gathering all data relevant to each theme 
 
Phase 4 
 
Review of themes 
 
Checking if the themes work in relation to the 
coded extracts and the entire data set, 
generating a thematic ‘map’ of analysis 
 
Phase 5 
 
Definition and 
naming of themes 
 
Ongoing analysis to refine the specifics of 
each theme, and the overall story the 
analysis tells, generating clear definitions 
and names for each theme 
 
Phase 6 
 
 
Producing report 
 
The final opportunity for analysis. Selection 
of vivid, compelling extract examples, final 
analysis of selected extracts, relating back of 
the analysis to the research question and 
literature, producing a scholarly report 
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2.1.5.1.1 Familiarize Yourself with the Data 
In this step, the researcher should be looking for potential patterns and 
themes. It can be started as soon as the data collection begins, using an iterative 
process, hand-in-hand with the transcription of the data source. Prior to reading 
the interview transcripts, researchers may create a ‘start list’ of potential codes. 
 
2.1.5.1.2 Coding Process 
Codes identify a feature of the data that appears interesting to the analyst. 
It refers to the most basic segment (element) of the raw data or information that 
is to be assessed in a meaningful way regarding the phenomenon. The coding 
process evolves through an inductive analysis and is not considered to be a 
linear process, but a cyclical one, in which codes emerge throughout the 
research process. The cyclical process involves going back and forth between 
phases of data analysis as needed, until one is satisfied with the final themes 
(Braun and Clarke 2006). Coding and data organization can be performed 
manually or using computer software (e.g. MAXQDA, XSight, NVivo). 
 
2.1.5.1.3 Search for Themes 
This phase involves sorting initial codes into potential groups (themes) 
and collation of all relevant data within the groups (Braun and Clarke 2006). 
Searching for themes and considering what works and what does not work within 
themes enables the researcher to begin the analysis of potential codes. It is 
important to begin by examining how codes combine to form over-reaching 
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themes in the data. At this point, researchers have a list of themes and begin to 
focus on broader patterns, combining coded data with proposed themes. 
Researchers also begin considering how relationships are formed between 
codes and themes and between different levels of existing themes. 
Themes differ from codes: themes are phrases or sentences that identify 
what the data means, describing an outcome of coding for analytic reflection. 
 
2.1.5.1.4 Revision and Confirmation of Themes 
 In this step, the initial candidate themes are reviewed. The phase requires 
the researchers to search for data that supports or refutes the proposed theory. 
At this point, the researcher has to decide which theme will have enough codes 
to support them, and/or which ones might be combined (Braun and Clarke 2006). 
Codes within themes should cohere together meaningfully, while there should be 
clear and identifiable distinction between themes. 
By the end of this phase, researchers have an idea of what themes are 
and how they fit together so that they convey a story about the data set. 
 
2.1.5.1.5 Definition of Themes 
 The following step is to define, refine and name the themes that will be 
presented in the final analysis. Identification of the essence of what each theme 
represents, what aspects of data each theme captures and how each specific 
theme affects the entire picture of the data is the most important part (Braun and 
Clarke 2006). 
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It is important to consider themes within the whole picture and also as 
autonomous (i.e. each theme separately), in order to identify whether current 
themes contain sub-themes and to discover further depth of themes. 
Researchers conducting thematic analysis should attempt to go beyond surface 
meanings of the data to make sense of the data and tell an accurate story of 
what the data actually means. 
 
2.1.5.1.6 Writing Report 
 The last phase of thematic analysis, following the review of final themes, is 
the production of the final report, presenting data analysis in a convincing and 
clear way (Braun and Clarke 2006). While writing the final report, researchers 
should decide on themes that make meaningful contributions to answering 
research questions, to be refined later as final themes. The goal of this phase is 
to write the thematic analysis to convey the complicated story of the data in a 
manner that convinces the reader of the validity and merit of the analysis: a clear, 
concise, and straightforward logical account of the story across and with themes 
to make the readers understand the final report. The write-up of the report should 
contain enough evidence demonstrating that themes within the data are relevant 
to the data set. 
 A fifteen-point checklist was developed by Braun and Clarke (2006) to 
summarize the thematic analysis, and to simplify the review process for 
researchers (Table 2.5). 
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Table 2.5 Fifteen-point check list for thematic analysis. 
  Adapted from Braun and Clarke (2006). 
 
PROCESS CRITERIA 
 
Transcription 
 
 
 
 
Coding 
 
 
 
 
 
 
 
 
 
 
Analysis 
 
 
 
 
 
 
 
 
 
Overall 
 
 
 
 
Written report 
 
1. The data have been transcribed to an appropriate level of 
detail, and the transcripts have been checked against the 
tapes for ‘accuracy’. 
 
 
2. Each data item has been given equal attention in the coding 
process. 
3. Themes have not been generated from a few vivid examples 
(anecdotal approach); instead, the coding process has been 
thorough, inclusive and comprehensive. 
4. All relevant extracts for each theme have been collated. 
5. Themes have been checked against each other and back to 
the original data set. 
6. Themes are internally coherent, consistent, and distinctive. 
 
 
7. Data have been analyzed, interpreted, made sense of rather 
than just paraphrased or described. 
8. Analysis and data match each other, the extracts illustrate the 
analytic claims. 
9. Analysis tells a convincing and well-organized story about the 
data and topic. 
10. A good balance between analytic narrative and illustrative 
extracts is provided. 
 
 
11. Enough time has been allocated to complete all phases of the 
analysis adequately, without rushing a phase or giving it a 
once-over-lightly. 
 
 
12. The assumptions about, and specific approach to, thematic 
analysis is clearly explicated. 
13. There is a good fit between what you claim you do, and what 
you show you have done. 
14. Language and concepts used in the report are consistent with 
the epistemological position of the analysis. 
15. The researcher is positioned as active in the research 
process: themes do not just ‘emerge’. 
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2.1.6 Challenges of Qualitative Research 
Just like any research model, qualitative research has to overcome some 
challenges: determination of a conceptual framework that is thorough, concise 
and elegant; development of a design that is systemic and manageable, but 
remains flexible; integration of these into a coherent unit (Marshall and Rossman 
1999). 
There is the perception within medical research suggesting that qualitative 
research is cumbersome and difficult to analyze. Some also suggest that 
analysis requires a high degree of interpretive skills, and that the number of 
participants being studied is too small (Pope and Mays 2000). However, this 
should not become an issue, provided that the data analysis is done well. 
Often, due to misunderstandings about the nature of qualitative methods 
and their use in healthcare, qualitative research is labelled as ‘unscientific’. 
Finally, the most frequent criticism is the subjective nature of qualitative research, 
implying that ‘subjective’ equals ‘biased’ or ‘prejudicial’. However, subjectivity 
stems from the fact that the researcher is also the tool that gathers data. Many 
qualitative tools are in place, and when used concurrently, they can guard 
against overly subjective research or identify the role of the researcher in the 
data collection (Pope and Mays 2000). 
 
2.2 KNOWLEDGE TRANSLATION 
Due to its relevancy to the data analysis process (see Section 2.5, below), 
the description of Knowledge Translation is included in this part of the thesis. 
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Knowledge translation (KT) is a “dynamic and iterative process that 
includes the synthesis, dissemination, exchange, and ethically sound application 
of knowledge to improve the health of patients, provide more effective health 
services and products, and strengthen health care systems” (Rogers 1983). 
Many methods of KT exist, including continuing medical education, clinical 
practice guidelines and systematic reviews, audit, feedback, and reminders, 
educational outreach, reward and punishment programs, and operative 
demonstrations. Previous studies have demonstrated that the majority of the 
above methods have done little to change physician practice. This has led to the 
conclusion that physicians are reluctant to change their practice, and that 
improved KT interventions are necessary. 
 
2.2.1 Diffusion of Innovations 
Diffusion of innovations is a theory within KT, popularized by Rogers 
(1983), that pursues an explanation of how, why, and at what rate new ideas and 
technologies spread (Rogers 1983). Rogers argued that diffusion is the process 
by which an innovation is communicated over time among the participants in a 
social system. 
The theory proposes that four main elements influence the spread of a 
new idea: the innovation itself, communication channels, time, and a social 
system. The process relies heavily on human capital, and must be widely 
adopted in order to self-sustain. The rate of adoption (defined as the relative 
speed at which participants adopt an innovation) is usually measured by the 
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length of time required for a certain percentage of the members of a social 
system to adopt an innovation. The rates of adoption are determined by an 
individual’s adopter category. In general, individuals who first adopt an innovation 
require a shorter adoption period (adoption process) when compared to late 
adopters. At some point, critical mass will be reached within the adoption curve 
(Rogers 1983), ensuring that the innovation is self-sustaining. 
Five categories of adopters have been identified: innovators, early 
adopters, early majority, late majority, and laggards (Rogers 1983). Diffusion 
manifests itself in different ways, thus being highly subject to the type of adopters 
and innovation-decision process. The criterion for the adopter categorization is 
innovativeness, defined as the degree to which an individual adopts a new idea. 
The process of diffusion entails a five-step decision making system. 
Adoption occurs through a series of communication channels over a period of 
time among the members of a similar social system. Integral to the theory are 
Rogers' five stages of the process: awareness (knowledge), interest 
(persuasion), evaluation (decision), trial (implementation), and adoption; an 
individual might reject an innovation at any time during or after the adoption 
process (Rogers 1983). 
 
2.2.1.1 Process of the Adoption of Innovation 
The first stage (Knowledge) occurs when the individual is first exposed to 
an innovation, but lacks information about it. During this stage, the individual has 
not yet been inspired to find out more information about the innovation. 
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The second stage (Persuasion) occurs when the individual is interested in 
the innovation and actively seeks related information/details. 
The third stage (Decision) occurs when the individual takes the concept of 
the change, weighs the advantages/disadvantages of using the innovation and 
decides whether to adopt or reject it. Due to the individualistic nature of this 
stage, this stage is the most difficult one on which to acquire empirical evidence. 
During the fourth stage (Implementation), an individual employs the 
innovation to a varying degree, depending on the situation. It is during this stage 
that the individual determines the usefulness of the innovation, and may search 
for further information about it. 
Finally, during the fifth (last) stage (Confirmation), the individual finalizes 
his/her decision to continue using the innovation. The stage is both intrapersonal 
(may cause cognitive dissonance) and interpersonal, and confirms that the group 
has made the right decision. 
 
2.2.1.2 Failed Diffusion 
Just because a diffusion failed, it does not mean that the innovation was 
adopted by no one; rather, failed diffusion often refers to diffusion that does not 
reach or approach 100% adoption. This is most likely due to its own weaknesses, 
competition from other innovations, or simply a lack of awareness. From a social 
networks perspective, a failed diffusion might be widely adopted within certain 
clusters, but fail to make an impact on more distantly related people. In addition, 
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over-connected networks might also suffer from a rigidity that prevents the 
changes an innovation might bring. 
 
 
2.3 STUDY SETTING 
This study, conducted at the London Health Sciences Centre and St. 
Joseph’s Healthcare Centre, in London, ON, Canada, was approved by the 
Research Ethics Board at the University of Western Ontario (Appendix I). 
Informed consent was obtained from each participant prior to the beginning of the 
study. 
In this study, we focused on a process question, exploring the 
dissemination of new knowledge (oncoplastic surgical techniques) to practicing 
surgeons, and how intra-operative mentoring as the mode of knowledge 
dissemination might change their already-established surgical practice. The main 
purpose was to examine the barriers and opportunities for adopting new 
techniques (such as oncoplastic surgery) at the University of Western Ontario, 
and to test the perception of those techniques by the surgeons before and after a 
period of intra-operative mentoring. 
Six surgeons participated in the study. Participants were selected from a 
group of attending general surgeons practicing breast surgical oncology at the 
University of Western Ontario. All breast general surgeons in London, Ontario 
agreed to participate in this study. The surgeons represented a spectrum of 
experience in breast surgery (both in volume of breast surgeries and years in 
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practice, ranging from first year of practice to almost 20 years of practice). All 
surgeons had subspecialty training in breast surgical oncology, or special interest 
in breast surgery; they worked on daily basis at three different locations across 
the City of London, ON (London Health Sciences Centre – University Hospital, 
London Health Sciences Centre – Victoria Hospital and St. Joseph’s Healthcare 
Centre’s Breast Centre). Most breast cases used for the intra-operative 
mentoring were seen, and had the appropriate surgical planning done, at St. 
Joseph’s Healthcare Centre. Surgeons were invited to participate in the study via 
e-mail invitations, sent by the principal investigator. 
 
 
2.4 DATA COLLECTION 
An interview guide (pre-intervention and post-intervention, Tables 2.5 and 
2.6, respectively) was compiled by the principal investigator, based on similar 
topics in the literature, as well as the data provided by other studies (Ritchie, 
Lewis et al. 2013). The initial guide was approved by the research team, and was 
adjusted throughout the process of data collection as needed. It was designed in 
semi-structured format with an open-ended question, to facilitate guiding the 
purpose of the study. 
All materials (study proposal, letter of information (Appendix II), details of 
the study, consent forms) were sent to participating surgeons via e-mail. All 
interviews were conducted by the principal investigator at one of the three above-
mentioned hospitals where the surgeons practice, according to their availability.   
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Table 2.1. Pre-Intervention Interview Guide. 
 
1. What kind of surgeries do you perform in your practice? Which ones do 
you consider yourself particularly experienced with and interested in? 
 
2. What is your opinion about oncoplastic breast surgery? What patient 
population you think will be suitable for oncoplastic techniques? 
 
3. What do you think would be the expected outcome from changing the 
current practice to accommodate those new techniques? 
 
4. What are your thoughts about the balancing procedure during and after 
the oncoplastic surgery? 
 
5. Have you performed this procedure in your practice? If so, how was your 
experience? If not, in your opinion, what are the barriers in applying 
oncoplastic techniques to your daily surgical practice? 
 
6. Would you be interested in exploring more about these techniques... why? 
If you are interested, in your opinion, what would be the best way to 
explore and learn more about these techniques? Are there any courses 
you know about or will be interested to join in order to learn more about 
oncoplastic surgery? 
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Table 2.1 – con’t. 
 
 
7. How useful do you think this surgical technique will be in the future and 
should it be part of the training curriculum for residents? 
 
8. Would you directly recommend this technique to your patients or do you 
refer your patients to an oncoplastic surgeon for a conversation about it?  
What’s the main criteria you follow for doing either? 
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Table 2.2. Post-Intervention Interview Guide. 
 
1. Can you tell me about your breast practice in the last few months. 
 
2. Can you tell more about any changes after a period of intra operative 
mentoring and discussion of various oncoplastic techniques. (impact of 
intraoperative mentoring). 
 
3. If there are any changes, how would you explain them? 
 
4. What do you think or how do you see oncoplastic surgery now from your 
prospective? 
 
5. During this period, how frequently did you think oncoplastic techniques 
were an option for your patients? 
 
6. Can you elaborate more on the techniques you have tried? 
 
7. Can you tell me about the patients’ perception and interest in oncoplastic 
surgery and how did it change their perception of surgery? 
 
8. What do you think were the barriers to adopt these techniques, in your 
opinion? 
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Table 2.2 – con’t. 
 
9. With the current health system in Canada, what would be the future of 
oncoplastic surgery? 
 
10. How do you think we can advance our knowledge and skills in oncoplastic 
surgery and how would this change your future practice? 
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On the day of the interview and prior to its conduction, the study purpose, 
requirements and stages were explained in detail to the surgeons. Consent forms 
were reviewed, and all questions that may have arisen were answered. 
 
2.4.1 Pre-Intervention Interview 
Each surgeon was instructed to answer the questions within their comfort 
level, and to ask for any explanations as necessary. They were also informed of 
having the right to refuse to answer any of the questions, or request that the 
recording be stopped if the need was felt. All interviews were recorded with two 
recording devices. Each interview lasted approximately 45-60 minutes, with 
questions adjusted according to the flow of the discussion.  
 
2.4.2 After the Pre-Intervention Interview 
Following the pre-intervention interview, a 6-week period of mentorship 
was allocated for all the surgeons. During this period, a detailed discussion and 
intra-operative illustration of different oncoplastic techniques was carried on. The 
principal investigator, who is also a mentor, reviewed each surgeon clinic and 
operation list to find the possible candidates for oncoplastic surgery, then make 
themselves available at the time booked for the patient to meet with his surgeon 
to have a more detailed discussion and hands on teaching on the planning 
required to perform oncoplastic techniques. At the same time, surgeons were 
advised to contact the principal investigator for any possible cases that may 
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benefit (in their opinion) from oncoplastic surgery to have further discussion 
about it. 
In the clinic, the principal investigator of the study then discussed the 
clinical picture of the patients, and the feasibility of certain techniques with the 
surgeon. After reaching an agreement/consensus about the procedure to be 
used for the treatment of that patient, the patients themselves would then 
participate in the discussion and the plans for their surgery. Patients were 
informed about the planned surgical technique. Once the patient approved and 
signed the informed consent, all other pre-operative procedures were carried out 
as usual. 
On the day of the operation, the surgeon reviewed the plan with the 
principal investigator and the patient, including pre-operative markings. The 
procedure started with a timeout announcement, stating the oncoplastic 
procedure that was planned (Kozusko, Elkwood et al. 2016). During the surgery, 
discussions continued with the individual surgeon, providing explanations of 
different possibilities and options, as well as the intra-operative techniques. Post-
operative care of the patient continued as usual, with the post-operative period 
instructions provided to the patient. 
Following the six weeks of mentoring, all surgeons were given a period of 
two months to apply the different technique and practice to the appropriate 
patients of their selection in their clinical practice. It is important to note that the 
principal investigator, who was also the mentor in this study, is fellowship-trained 
in breast oncology and reconstruction, and an oncoplastic surgeon who 
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previously attended numerous master classes and courses of oncoplastic 
surgery in Europe and the United States. The mentor was a fellow in Breast 
Surgical Oncology in London, Ontario and was working with all the participant 
surgeons during the time this study was conducted. 
 
2.4.3 Post-Intervention Interview 
 The second round of interviews was carried out by the principal 
investigator, as a follow-up to the period of mentoring. As before, the interviews 
were carried out across all three hospital sites at the times convenient to each 
surgeon. The interviews had an identical, semi-structured format as before, and 
lasted approximately 15-30 minutes. The post-interview guide was more focused 
on the period of mentoring and various oncoplastic surgery techniques. 
 
 
2.5 DATA ANALYSIS 
 A professional transcription services centre transcribed the interviews. All 
interviews were anonymized, to preserve the confidentiality of each study 
participant. The principal investigator reviewed all transcripts for accuracy, before 
they were analyzed. 
 The interview transcripts were analyzed using a coding process with three 
iterative phases, as described in thematic analysis (section 2.1.5). Based on the 
first two interviews, the principal investigator used the initial coding to identify the 
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 Themes were applied to the next two transcripts, to refine and expand the 
developing categories. Following further team discussion, preliminary categories 
were iteratively developed and refined by analyzing the entire dataset. True to 
the iterative nature of constant comparative analysis (Charmaz 2006), additional 
initial codes were also added. Theoretical coding then enabled for more explicitly 
linking categories, and to theoretically conceptualize findings. As the analysis 
evolved, the theoretical coding was blended with notions from the diffusion of 
innovation theory that were used as sensitizing concepts. 
 The ‘sensitizing concept’ was referred to by the sociologist Charmaz 
(2006) as “those background ideas that inform the overall research problem”.  
The concept is normally used as a starting point in qualitative research, where 
usually there is no hypothesis, but rather a way to discover and understand an 
experience, or a phenomenon (Bowen 2006). 
 The principal investigator debriefed with all the team members at each 
stage of the analytical process (Thurmond 2001), to ensure rigor, credibility, 
originality, resonance and usefulness of the data generated (Charmaz 2006). 
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CHAPTER 3. RESULTS 
 
This study was designed to identify and understand factors that contribute 
to the slow uptake of oncoplastic surgery, both broadly within the Canadian 
healthcare context and specifically, at the University of Western Ontario in 
London. The results that emerged from the qualitative analysis of this surgical 
mentoring intervention, described in the previous chapter, are presented. 
The intervention was conducted over a six-week period, and consisted of 
perioperative mentoring with pre-surgical discussion, intra-operative guidance 
and post-operative feedback. In order to assess the appropriateness and 
effectiveness of the intervention as a method for teaching new surgical skills to 
practicing surgeons, pre-intervention interviews were conducted to assess the 
prior knowledge of each participant, and to gain an understanding of their specific 
perceptions and willingness to incorporate oncoplastic techniques into their 
practice. Post-intervention interviews were conducted two months after the 
conclusion of the intervention, to assess how surgical mentorship affected 
participants’ knowledge of oncoplastic surgery, their perceptions of its usefulness 
and their degree to which the new surgical techniques were incorporated into 
their practice. 
 
3.1 PRE-INTERVENTION INTERVIEWS 
The pre-intervention interviews generated significant insights into the pre-
existing knowledge that participants held about oncoplastic surgical techniques, 
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their perceptions of the outcomes and their willingness to incorporate them into 
their surgical practice. Participants were also asked to reflect generally on their 
breast cancer practice, as well as on the various surgical techniques they 
routinely employ. The pre-intervention interviews provided rich descriptions of the 
ways that the participating general surgeons understand, manage and treat 
breast disease. The results suggest that there are important differences in the 
surgical management of benign and malignant breast disease, and that these 
approaches are, in part, a reflection of the outcomes prioritized by surgeons for 
each condition. While cosmetic outcome was described as being a central 
concern in the management of benign breast disease, the outcome was not 
considered to be as important in the treatment of malignant breast disease. In the 
case of malignancy, surgeons prioritized an adequate resection with negative 
margins over cosmetic outcome. Although the appearance of the post-surgical 
breast was not of primary importance in malignant cases, the surgeons indicated 
that they used cosmetically appealing incisions whenever possible.  
Despite the fact that aesthetics were not of primary importance, the 
surgeons interviewed in the study consistently described the overall cosmetic 
outcome in malignant cases as being generally good. However, participants 
conceded that in the cases of large cancers, standard lumpectomy techniques 
are not able to yield an acceptable cosmetic outcome; in these cases, 
mastectomies are often performed. These were the cases that figured centrally in 
the discussion of the pre-intervention interview, during which the participants 
were prompted to reflect on the appropriateness and effectiveness of oncoplastic 
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surgical techniques in cases where the standard procedures cannot yield 
optimum cosmetic outcomes.  
During the pre-intervention interview, it was established that oncoplastic 
surgery was a term known to all participants. Each surgeon was asked to define 
oncoplastic surgery, as well as to describe how he/she understood the practice 
and the techniques with which it is associated. The results indicated that the 
general surgeons interviewed did not share a single, uniform understanding of 
oncoplastic surgery. The participants had varying levels of knowledge and 
different understandings of oncoplastic surgery. Across the various definitions, 
however, oncoplastic surgery was consistently described as a practice that is 
associated with improved cosmetic outcomes. Participant 6 defined oncoplastics 
as an evolving sub-specialty that prioritizes the aesthetic appearance of the 
breast: 
“I view it as a blend between general surgery and plastic surgery, sort of 
an evolving subspecialty of surgical oncology.  It’s using plastic techniques 
to try to improve the outcome cosmetically for patients.” 
 
Similarly, participant 1 explained that oncoplastic surgery as a complex surgical 
practice that is both “oncologically safe” and breast conserving: 
“Generally, oncoplastic surgery to me means performing an oncologically 
safe surgery on the breast that generally involves breast conservation 
using plastic surgery techniques that optimize the cosmetic outcome at the 
same time, which generally means trading more extensive surgery or 
scars for a better shaped breast.” 
 
 
The definition offered by the participant 2 also highlighted the centrality of 
aesthetic outcomes in oncoplastic surgery, but also emphasized that its scope is 
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limited to the malignant breast, clearly separating oncoplastic techniques from 
those associated with plastic surgery: 
“To me, oncoplasty means techniques of doing a cancer operation with a 
better cosmetic outcome, but in my mind, this is not talking about 
reconstruction.  This is talking about dealing with the procedures in the 
native breast.” 
 
The various definitions of oncoplastic surgery provided by the surgeons 
interviewed in the study were consistent in their acknowledgement of the hybrid 
nature of the practice, its relationship with plastic surgery, and the cosmetic 
benefits associated with it. However, the relationship between the elements and 
the ways that they figured within the definitions was diverse. Our findings indicate 
that the practice of oncoplastic surgery has yet to be integrated and incorporated 
into surgical practice in London, Ontario in a meaningful way. Furthermore, the 
differences between the definitions also provide an important insight into the 
surgeons’ knowledge and perceptions of this nascent sub-specialty. 
 
3.1.1 Knowledge of Oncoplastic Surgery 
The pre-intervention interviews provided important insights into the level of 
technical knowledge the general surgeons had about oncoplastic surgery. The 
knowledge base of participants was varied, and while some surgeons reported a 
general familiarity with the practice and its basic techniques, others also related 
specific information about oncoplastic techniques and their clinical applicability. 
For example, participant 1 demonstrated their knowledge of oncoplastic 
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techniques through their description of the characteristics of level 1 and level 2 
techniques: 
“I use the nomenclature that I think pretty standard for what we call 
oncoplastic surgery, which is differentiating breast conserving surgery into 
small lumpectomies with a volume loss of less than 20%, where if the 
breast tissue is not too fatty, the skin and chest wall layers can be 
mobilized so that the intervening gland can be primarily closed to close the 
defect.  And level II where the defect is closed, but additional skin is taken 
and the nipple is recentralized in order to create a smaller, but balanced 
and cosmetically pleasing breast mound.” 
 
This participant had a keen interest in oncoplastic surgery, and also reported 
using specific level 1 techniques such as a ‘glandular closure,’ in their pre-
intervention practice, as well as some more complex level 2 techniques, such as 
nipple recentralization. 
In sharp contrast to the specific knowledge of oncoplastic techniques by 
participant 1, other participants had very cursory knowledge of oncoplastic 
surgery and no knowledge of specific techniques. For example, participant 3 
described their understanding of oncoplasty in very general terms, stating: 
“It means respecting the oncologic needs of the surgery, so first and 
foremost not to compromise your margin.  Oncologic safety is the first 
consideration, but within that parameter, to try to achieve the best 
cosmetic appearance of the breast along with a safe cancer operation.  I 
know they’re divided into different levels.  I can’t remember if it’s A, B, C or 
1, 2, 3 and everybody is supposed to be able to do level 1, that’s about all 
I know.” 
 
The precursory nature of this participant’s knowledge rendered it challenging for 
the surgeon to describe the clinical benefits of oncoplastic techniques and how 
such techniques could be applied within his/her practice.  While the majority of 
participants reported a generally favourable opinion of oncoplasty, other 
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surgeons, like participant 3, expressed uncertainly about the clinical value of the 
practice; participant 5 overtly challenged the relevance and clinical advantage of 
oncoplastic surgery: 
“People use the oncoplastic techniques, but I find it a fairly rare thing to 
use, that’s all. I just don’t identify a ton of patients that I would use it in, 
that’s all, because there’s a bunch of limitations to it. In other words, you 
have to have breast tissue that’s reasonable, and so you have to have a 
patient that has reasonable breast tissue, rather than fat. I don’t know, I 
just… I’m still struggling to understand how I would fit oncoplastic 
techniques into my practice. I just don’t know, in my practice, that there’s 
that many.” 
 
Participant 5 elaborated on their opinion that oncoplastic surgery was of limited 
value for their practice by drawing on the specific demographics of their patient 
population: 
“In other words, you have to have breast tissue that’s reasonable, and so 
you have to have a patient that has reasonable breast tissue, rather than 
fat.  The patients I struggle with are the DCIS patients, in an older woman 
on a mammogram, they’re 70 years old, they got … really, all of their 
breast tissue is all just fat.  You can’t move that around.” 
 
In the pre-intervention interview, the surgeons were asked to describe 
their opinions of oncoplastic breast surgery to generate insight into why the 
practice has yet to be substantially incorporated into their local practice. 
Participants were aware that oncoplastic surgery is a well-established practice in 
Europe, and is emerging as a standard practice. Participant 1 commented that 
while the speciality is “brand new to Canada,” the importance of the practice is 
becoming apparent: 
“It’s becoming increasingly appropriate to do, but the vast majority of a 
blade of breast surgeons don’t know how to do it and are still at the 
learning phase about how to modify their surgery in a way that improves 
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the outcome aesthetically.  Most surgeons probably haven’t given it as 
much thought as they should to a good cosmetic result.” 
 
Furthermore, participant 2, a senior surgeon with extensive expertise in breast 
surgery, communicated the increasing relevancy of the practice in Canada by 
stating: 
“If I was training now to be a breast surgeon, I would definitely want to be 
able to do as much oncoplastics as the European surgeons are doing by 
myself.”  
 
This view was supported by participant 1, who recently sought out and completed 
oncoplastic courses, to allow them to incorporate some techniques into their 
practice. Gaining expertise in this area was described as being important for this 
participant, so that the surgeon could deliver a high standard of care in their 
breast practice. To this effect, the surgeon stated: 
“This procedure really should be done on almost everyone that has breast 
conserving surgery, barring elderly fatty replaced breasts where a simple 
lumpectomy of a small amount of disease could be done.  But barring that, 
most people you could approach with either the glandular closure or a 
more complex type of mound revision to permit for a good breast shape 
while doing a lumpectomy.” 
 
While the participant 1 and 2 deemed oncoplastic techniques to be both 
important and relevant for their practice, other surgeons expressed hesitancy 
about adopting these surgical techniques, in light of their limited knowledge of the 
practice. For example, participant 3, who reported attending some presentations 
on oncoplastic techniques, emphasized 
“I don’t consider my knowledge to be anything but superficial, though. I 
wouldn’t like to teach or talk to a resident about oncoplastic techniques 
because I don’t feel I have enough knowledge for that. I know there are 
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some simple techniques, that sort of bat wing thing which I don’t really 
understand and have never tried.” 
 
This surgeon’s reflection demonstrates how constraining are the limited exposure 
to oncoplastics, as well as opportunities for practicing breast surgeons to learn 
about and to practice, are to the possibilities for surgeons to incorporate 
oncoplastic techniques into their practice. This account highlights that, in order 
for new surgical techniques to be successfully introduced into practice, general 
surgeons need to have access to training incorporating opportunities to practice, 
and to receive feedback from experts. The finding supports the appropriateness 
of mentorship as a surgical intervention for teaching new techniques. 
 
 
3.2 INTERVENTION: MENTORSHIP PROGRAM 
The findings of the study have demonstrated that mentorship is an 
effective and desirable method to teach new surgical techniques in a manner that 
supports their adoption and incorporation into practice. Participants in the study 
consistently described their desire to learn new techniques from a surgeon who 
had expertise in that particular skillset, and who could support them during their 
hands-on practice. This method was described as being preferable to self-
learning: 
“When I am doing the simple things, I have looked at doing some of the 
things that they describe, but I don’t feel that I would be happy to go 
ahead with that without somebody who has done that procedure and is 
comfortable with it with me. I don’t learn very well from a book, for 
sure. So, I really like to do it with someone. “ 
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In the post-intervention interview, the surgeons were asked to comment 
specifically on the mentorship intervention as a method to facilitate their adoption 
of new techniques. The majority of responses were supportive of the use of this 
method as useful and efficient to educational intervention. One participant related 
how the hybrid approach of the mentorship provided them with a valuable, and 
efficient learning opportunity: 
“I think I’ve had a good variety of cases, especially just having started 
here. When we had talked, I hadn’t done very much, I don’t think, at that 
point. I was just starting out. I’ve done a lot of lumpectomies, a lot of 
mastectomies, and decision-making around one or the other, and so on.  
I’ve had a chance to do some oncoplastic techniques, both with you in the 
operating room, as well as a few on my own. I think I have a better sense 
of who to consider for the different procedures, like the Level 1 and the 
Level 2. In fact, I had one lady whom I did like a therapeutic mammoplasty 
with Dr. X, which I felt I wouldn’t have really been comfortable offering or 
understanding how that would go if I hadn’t had any of the training, or the 
background I had. “  
 
Participant 1, who had described their interest and adoption of oncoplastic 
techniques in their practice during the pre-intervention interview, found that the 
mentorship experience affirmed their belief in the importance and relevance of 
oncoplasty for their practice: 
“I think it validated it. For me, I was pretty convinced, even a bit before the 
intervention, but I became more certain as a result of the intervention. I 
really could see clearly the benefit for virtually all patients, and the benefit 
of discussing it with other people, in terms of coming up with ideas that I 
hadn’t thought of. “ 
 
Given the limited scope of the study, the mentorship intervention offered 
had some limitations; specifically, the length of the intervention was confined to 
six weeks. Given the unfamiliarity and complexity of oncoplastic techniques, 
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study participants reported that the period of mentorship was not sufficient to 
familiarize themselves with all oncoplastic techniques, particularly those that are 
used infrequently. Moreover, the incorporation of oncoplastic techniques into 
surgical practice was complicated by the degree of both knowledge and 
imagination involved in the clinical decision-making process. Reflecting on the 
limitations of the intervention, one participant commented: 
“I suspect that if you were mentoring someone over a period of six months 
or so, you probably would get a couple of examples of the basic 
techniques to try, like to practice on during that amount of time.  I felt as 
though I had seen a lot of useful techniques that I could learn, but I didn’t 
quite feel confident in trying them without someone there to say yeah, 
you’re doing it, that’s the right way, that kind of thing.” 
 
 
3.3 POST-INTERVENTION 
At the conclusion of six weeks of perioperative mentoring and discussion, 
participants returned to their own practices, where they incorporated the 
application of the new techniques they had learned. A second round of interviews 
was conducted following a two-month interval, to gain an understanding of how 
the period of mentoring and introduction of oncoplastic surgery affected the 
practices of the breast surgeons. 
The surgeons enrolled in the study reported that mentorship increased 
their knowledge of oncoplastic surgery, and provided them with an opportunity to 
familiarize themselves with previously unknown surgical techniques, while also 
gaining the confidence to apply the new skills in their breast practice. 
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Participant 2, for example, described how they incorporated skin excision 
and measurement techniques introduced to them during mentorship into their 
practice in the eight weeks following the intervention: 
“So, before that, I had not had a lot of experience doing anything that 
involved removing skin.  I had done some moving breast flaps underneath 
and closing dead space, but I had not done measurements or skin 
excision.  So, in the last two months, I did several cases where I did a 
circumareolar excision of the skin, so basically a reduced volume of the 
breast.  And I did some with a wing excising some of the lateral breast, 
and then actually doing elliptical incision around the nipple to move the 
nipple and adjust for the shape and the volume reduction.” 
 
For this participant, the period of mentorship was an effective intervention 
because it increased their knowledge of oncoplastic surgery, as well as the 
advanced technical skills required to successfully implement their new 
knowledge. Similarly, participant 6 described implementing sophisticated 
oncoplastic techniques during the post-intervention period that they had not 
previously used in their breast practice: 
“I had done a couple racket-type incisions or racket-type procedures for 
tumors in the upper outer and lateral, like lateral aspect of the breast.“ 
 
The results of the study also suggest that surgical mentorship was an 
effective intervention for improving surgeons’ knowledge of the clinical 
advantages of oncoplastic surgery and the specific clinical contexts in which the 
techniques can be optimally applied. Participant 2 reflected that during the period 
of mentorship, their understanding of relevance of oncoplastic surgery in their 
breast practice improved: 
“I think it offers advantages that I did not see in the past, and it would 
involve a greater percentage of women than I thought in the past. So, my 
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general feeling is that a surgeon who does breast surgery in a reasonably 
large volume would be motivated enough to do this surgery to see the 
good results.” 
 
 
In addition to recognizing the broad applicability of the techniques for the general 
patient population, participant 2 also described how the surgeon had come to see 
oncoplastic surgery as worthwhile practice for busy breast surgeon’s practice, 
and more importantly, as a set of techniques that could increase the satisfaction 
of both patients and surgeons: 
“I think that, basically, a lumpectomy is not a very rewarding operation for 
a surgeon. There’s no nice anatomy. There are no nice landmarks. It’s not 
a beautiful procedure, so oncoplasty does offer a little bit more of a 
challenge to the procedure, and a little more of the person’s input into the 
operation, so that can be rewarding.” 
 
Participant 6 reflected that, as a result of the mentorship and their 
increased knowledge of oncoplastic techniques, they have incorporated more 
breast conserving techniques into their practice, reducing the number of 
mastectomies they perform: 
“Now I know what other possibilities I can offer a patient, or at least I’ve 
got more possibilities, anyway. It will, for sure, change my practice 
because I will be continuing to think about ways that, if I have to do a very 
large lumpectomy, I will feel like ‘well, it’s not necessary, how can we 
avoid a mastectomy for this patient’.  And so, I don’t know that I would 
have necessarily always gone that route in my thinking before having had 
this period of a little bit of learning, both with the material given and the 
one-on-one, and the feedback and things like that.” 
  
Participant 5, who had reported in the pre-intervention interview that they 
did not see the relevance of oncoplastic surgery for their practice, described 
post-intervention how their increased knowledge of the techniques enabled them 
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to identify specific cases in their practice for which oncoplastic surgery would be 
beneficial. The participant described how the surgeon successfully incorporated 
the techniques into the treatment of a younger patient: 
“Well, I tried one of the oncoplastic techniques. I think it was a racket… 
well, I was happy with the way it turned out. I could see the benefit in that 
particular young woman. I still think it has limited applicability, but just to 
identify the cases that it would work in is fine. I still think there’s just a 
small proportion of the women that would really benefit from it.” 
 
However, despite the account of their successful application of oncoplastic 
techniques in their practice, the opinion of participant 5 was not fundamentally 
transformed in terms of relevance of oncoplastic surgery to their practice. 
 
3.3.1 Effect 
In the post-intervention interviews, participants were asked to reflect on 
how the intervention and their training in oncoplastic techniques might affect their 
breast surgery practice in the future. The results indicate that the mentorship 
intervention enabled surgeons to identify cases where oncoplastic techniques 
could improve cosmetic outcomes, enabling them to optimally incorporate the 
new techniques into their surgical plans. Participant 6 described how the 
perioperative discussions and surgical mentorship during the intervention 
provided them with an opportunity to confidently incorporate the new knowledge 
into their practice and consultations with patients. The surgeon related that 
before the intervention: 
“I wouldn’t have really been comfortable offering or understanding how 
that would go, if I hadn’t had any of the training, or the background I had.  
Which is not extensive, but at least I’m thinking about it in a different way 
 98 
because, otherwise, this woman would have had a mastectomy for sure, 
no questions asked, had we had not gone that other route.” 
 
 Participant 3 described how the surgical intervention and their increased 
knowledge of oncoplastic surgery had made breast conservation as more central 
consideration in their preoperative planning. In particular, the surgeon related 
how their clinical decision-making practices altered for patients presenting with 
large cancers who may benefit from oncoplastic techniques: 
“I think it probably increased my willingness to try to, for instance to 
preserve the nipple area where a complex one, that something was a little 
bit close. And as I said for lower, not just lower poles six o’clock lesions 
but anything in the lower half of the breast I’ve changed my way of looking 
at those. I used to say ‘well, if it’s too small a breast it’s just going to be a 
disaster and I should just do a mastectomy’ and now I’m thinking I should 
at least talk to somebody about whether an oncoplastic technique could 
be used to do a breast-conserving operation.“ 
 
While the mentoring intervention increased the surgeons’ knowledge of 
level 1 and 2 oncoplastic techniques, the findings suggest that continued 
mentorship and support are required for the successful integration of these into 
practice. For example, participant 1 was hesitant to complete advanced 
procedures by themselves, and adopted the strategy of combining their more 
complex surgical cases with the plastic surgery team in order to access 
continued support: 
“I still don’t feel comfortable doing what I would call level 3 cases by 
myself. I think I now feel comfortable to do a variety of level 2 oncoplastic 
procedures, where you are reducing some of the skin envelope as well as 
the lumpectomy. But the reduction by myself, I don’t feel comfortable yet 
with the markings, I don’t have enough experience to really do it totally by 
myself. Because I have a plastic surgery backup, I’ve been really making 
all of those cases be combined cases, and it has worked out really well, I 
think.” 
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Participant 1 further reflected on the challenges the surgeon experienced 
incorporating oncoplastic techniques, and identified moments where continued 
mentorship would have provided them with both, the support to be ‘brave’ in the 
operating room and the assistance they needed to work through the difficulties 
that arose during the surgical procedure: 
“I found sometimes that it was more challenging than I thought, where I 
would rotate the glandular rotation and it doesn’t quite fill the defect. Or it 
fills it, but it’s still rumpley-looking and I just don’t have the volume 
experience to be comfortable that it will settle out, and so I worry that 
there’s going to be excess fat necrosis or volume loss or contour 
deformity, and I worry that I haven’t done it right or sufficiently well. Those 
things made me hesitate probably more than I should. I don’t feel brave 
necessarily to embark on big contour changing procedures and, for that 
reason, I haven’t been brave enough to do my own breast reductions on 
the affected cancer side fully alone. I still want the outcome to be optimal.  
I have slowly increased my experience over time and it’s becoming a 
larger portion of my practice.” 
 
The long-term effects of the mentorship cannot be evaluated, given the 
limited scope of the study. The nature of breast surgery and the long recovery 
process for patients also render it difficult to assess the implications of the 
intervention for the surgeons’ future practice. The post-intervention interviews 
were conducted before the surgeons had an opportunity to follow-up with the 
patients who had received oncoplastic surgery, and thus could not comment on 
the potential positive cosmetic outcomes. While the feedback about the 
outcomes of the cases where the participating surgeons tried oncoplastic 
techniques was generally good, all participants agreed that cosmetic result could 
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not be accurately assessed until after the patients finish their radiation treatment, 
which is a major contributor to the less desirable cosmetic outcome after surgery. 
Reflecting on one of their cases, participant 2 mentioned that 
from a shape point of view, I was very pleased.  I’d have to say it was very 
good”, 
 
but also emphasized that they 
“…have not seen these cases after the radiation, which I would be very 
anxious to see, and they probably will be about ready to see that now, but 
I was pleased with the healing. I did not have any issues with unusual 
pain. I did not have any infection, and it did not feel there was fat necrosis 
or any other problems with the healing.” 
 
Similar to participant 2, another surgeon emphasized that the potential benefits of 
oncoplastic surgery are not yet visible, affirming that surgeons need to look to the 
long-term results in order to assess the usefulness of the techniques: 
“As I said, I think that the real benefits are what we’re seeing in the long-
term, not what we’re seeing in our immediate post-op visits. It’s after the 
radiation that you can really feel that you made a difference for the 
patient.” 
 
 
Thus, the currently unknown long-term cosmetic outcome and satisfaction 
of patients remain unknown, and may have an effect on how participants 
perceive the clinical value of oncoplastic surgery.  
 
3.4 WORKING WITH THE PLASTICS TEAM 
Oncoplastic surgery, as the term suggests, combines techniques from 
plastic surgery with oncological surgical techniques. Given the centrality of 
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techniques derived from plastic surgery in this practice, the plastic surgery team 
are integral to the adoption of oncoplastic surgery in a general surgery breast 
practice. In the post-intervention interview, we asked the surgeons to describe 
their relationship with the plastic surgery team, and to reflect on the possibilities 
for collaboration between the two specialities in the future, in order to promote 
oncoplastic surgery. 
During the course of the intervention and in the post-intervention period, 
participant 2 reported that the plastic surgery team had been very willing to 
collaborate during oncoplastic procedures. They remarked: 
“In our centre, I think we are very fortunate. I have never had any kind of 
response other than enthusiasm for anything that I wanted to do, including 
booking with them if we were doing a major lumpectomy, an adjustment of 
the other side, or a lumpectomy combined with a full reduction.” 
 
Another surgeon reflected that while they anticipated tensions to arise around the 
division of labour in oncoplastic procedures, these had not materialized in the 
local setting: 
“I think, in general, maybe it’s an area of contention about who does the 
reduction, and who does the other side, and who does the major 
oncoplastic procedures for large lesions.  However, I think here, our 
plastic surgeons are so overwhelmingly busy with the work they already 
have, and we have a good working relationship that I have never detected 
any issue related to who does what, or working together, or trying to 
accommodate.” 
 
While the surgeons interviewed for the study reported experiencing 
productive, collaborative relationships with plastic surgeons in their local hospital 
context, participants acknowledged the potential for the adoption of oncoplastic 
techniques to cause conflict between plastic and breast surgeons. For example, 
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participant 4 highlighted the potential for oncoplastic procedures to cause political 
problems between specialties: 
“I would say, like every other hybrid specialty or subspecialty that is 
evolving in medicine, [it] depends where you are. There will be areas 
where it’s very collaborative, and people are very happy to share it, but 
politically, in other areas, it would be very difficult. There would be, I’m 
certain, centres where general surgeons would view it as their domain, 
and plastic surgeons would see it as their domain, and there would be 
conflict.”  
 
Another surgeon described plastic surgeons, particularly those with 
prominent practices, to be the “greatest challenge” to the acceptance of 
oncoplasty in Canada, but was optimistic about the potential for collaboration 
between the two specialties in the future: 
“With regard to other specialties, the plastic surgeons, I think, are the 
greatest challenge in terms of acceptance of the procedure. Especially 
older, well-established plastic surgeons are fearful that it will be a turf 
battle between specialties over cosmetic elective breast cases, if we start 
doing these procedures increasingly. There’s a lot of underlying tension 
still, about that. I think it will take time, but I think it will ultimately resolve.  
Because in Canada, where resources are constrained, it works best to 
work in combination, rather than in isolation, and so I think it will end up 
staying a shared field.” 
 
 
3.5 BARRIERS FOR ADOPTION OF ONCOPLASTIC SURGERY 
3.5.1 Outcome Satisfaction 
The findings of the study illuminate a number of important factors that 
hinder the adoption of oncoplastic techniques in the breast general surgical 
practices in London, Ontario. One important and unexpected barrier identified 
was the high level of satisfaction reported by surgeons and patients with their 
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current surgical practices. Superficially, the surgeons interviewed in the study 
consistently stated that they were satisfied with the oncological and cosmetic 
outcomes of their current standard practice. Participant 6 described how 
professional satisfaction with current practices poses a barrier to the 
incorporation of breast-conserving techniques: 
“There are a lot of general surgeons both in academic centres and 
community centres that just don’t really believe that this is something that 
needs to be improved upon.  They don’t see this as a problem that needs 
to be solved but the thing is you can change minds when you show people 
the results of like you don’t have to do a mastectomy.  You can actually 
take out this much breast tissue.  And if you use these techniques you do 
not have to do a mastectomy and you save that patient reconstruction and 
big surgery and so on.  It’s hard though.  I don’t know how to do that 
without, like you know, there is a lot of I think prejudice about it.  I think 
that people feel like, again like it’s a problem that doesn’t need to be 
solved.“ 
 
Given the challenges of incorporating new surgical techniques, particularly 
those that draw on techniques from other specialities, it is unlikely that surgeons 
will be motivated to change their practice to incorporate oncoplastic surgery, if 
their current surgical outcomes are deemed to be satisfactory. As indicated by 
participant 2: 
“In order to adopt a new technique, you have to think that it’s substantially 
better than what you’re doing at the present time. And probably that the 
proportion of lumpectomy cases, that would benefit from an oncoplastic 
approach, are small enough that people think oh I’m doing fine.” 
 
To counteract this barrier, participant 6 suggested that surgeons need to 
be shown ‘the results’ of oncoplastic interventions, and to be exposed to cases 
where the use of oncoplastic surgery enabled the surgeon to avoid both 
mastectomy and reconstruction, and instead perform a smaller, breast 
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conserving surgery. This participant emphasized that while breast surgeons with 
well-established practices may be unlikely to adopt oncoplastic techniques, early 
career surgeons would likely be both interested in and receptive to oncoplastic 
surgery: 
“I think you’d have to start with people at the beginning of their careers 
rather than the ones at the end who may be less likely to want to learn any 
new tricks, so getting residents exposed to it and maybe residents who 
are interested in doing breast surgery or breast fellowships. Showing them 
what is possible because that might influence their interest in doing these 
extra courses or, doing an extra six months of their fellowship or year or 
what have you to get that experience, so maybe just picking the right 
people who are receptive to it. I mean, like I said, you may not change 
minds of people who are already set in their ways and are happy with their 
practice the way it is.” 
 
In addition to experiencing a high level of satisfaction with their current 
surgical practices, participants reported receiving little negative feedback from 
their patients about their cosmetic outcomes of their breast surgeries.  Participant 
6 reflected that 
“women don’t complain to me about this. They’re happy to have the 
mastectomy. Their cancer is gone, I feel like I’ve done a good job and they 
tell me I’ve done a good job, but when they don’t know the alternative then 
it’s not a completely […] it’s not the best outcome necessarily.” 
 
Another barrier to the widespread adoption of oncoplastic surgery is the 
fact that patients are largely unfamiliar with oncoplastic surgery and do not have 
an understanding of its cosmetic benefits. Participant 1 remarked that a number 
of patients that had been approached about oncoplastic surgery did not express 
an interest in the procedure or a desire for improved cosmetic outcome:  
“I think probably half of the patients that we offer oncoplastic surgery to 
probably don’t care, or they say they don’t care, at the time of the surgery, 
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and maybe they’ll be happier later. But they probably don’t have a huge 
vested interest, and probably the other half are completely delighted to 
have a breast reduction built into a cancer operation, so they see it as a 
bonus. They probably don’t appreciate that it’s so much better long term, 
from a cosmetic perspective, because they don’t know what it would have 
looked like if they hadn’t had it done. They probably never really even 
appreciate how bad it would have been if we had just left the contour 
deformity.” 
 
Given the overwhelming experience of the disease and its treatments, 
patients often prioritized good oncological outcomes, and considered cosmetic 
outcomes to be less important. Patient perceptions of their surgical outcomes are 
further complicated by their limited knowledge of the cosmetic outcomes of 
various surgical practices. For example, participants commented that patients are 
often unaware that their cosmetic outcome would have been different if 
oncoplastic surgical techniques were not used: 
“You know, I must say it’s the same as … I don’t think they know the 
difference, so on an individual patient basis they don’t know that the 
procedure was done differently than it could have been done. They just 
assume that’s the way it was done. Generally, people are happy with it. 
They’re typically overwhelmed with the cancer diagnosis, and are most 
interested in getting on with the next steps of their treatment. But, it’s, I 
think, down the road my impression is that once people get through the 
initial cancer treatment and they’re starting to feel more like themselves 
again, that’s when at least they raise concerns about whether cosmetically 
you can do something about their breasts. So, I think the benefit will be 
down the road. You won’t have people wondering should I go see a plastic 
surgeon and can I have something done to this lumpectomy site.” 
 
In the example above, participant 4 speculated that the cosmetic benefits of 
oncoplastic surgery may not be appreciated by patients until after the first post-
surgical year when patients have completed their primary treatments. The 
experience of breast cancer and the prolonged nature of the treatments delay 
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patient feedback about their surgical satisfaction, and in the case of surgical 
innovations, may make it challenging for surgeons to assess the benefits of 
oncoplastic surgery in their practice in the short term. 
 
3.5.2 Canadian Healthcare System 
The introduction of new techniques and technologies into healthcare 
practice do not occur in a vacuum, but rather are negotiated within the complex 
context of the Canadian healthcare system. The structure of the Canadian 
healthcare system both shapes and constrains the possibilities for the adoption 
of new techniques. Techniques that fit seamlessly into the existing structure are 
adopted at a much greater rate than those that challenge one or more practices 
within the structure.  In the case of oncoplastic surgery, the results of the study 
suggest that the structure of the Canadian healthcare system is largely perceived 
to be a barrier to uptake. 
Participant 1 identified a number of structural barriers that make the 
adoption of oncoplastic surgery in Canada challenging, including the need for 
ongoing mentorship, billing limitations and the increased resources required to 
complete more complex surgeries: 
“For practicing surgeons, the first barrier is having people to discuss this 
with, or to bounce this off, after the intervention period. I think we would 
need regular discussion opportunities of cases, just to increase the 
confidence. Because every tumor and every patient and every contour is 
different. I think there are still remuneration barriers, so there is no billing 
code for that procedure, and I think that’s a barrier to the community 
surgeon in terms of income, and that they don’t want challenges around 
billing and repayment. And time: it takes more time, which is sort of linked 
to income, but we are resource-constrained, and so I could see how, if you 
had a number of cases to do, that you would feel like you can’t spend an 
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extra two hours on this one patient, when that’s whole other cancer patient 
that has to wait longer.” 
 
Other participants identified the increased human resources required for 
oncoplastic surgery as a significant barrier. Participant 4 noted that each 
oncoplastic procedure would require additional clinical time, to explain the 
complexity of the procedures to patients, as well as additional operative time. In 
the Canadian context, where there are increasing concerns about the length of 
patient wait times and the overburdened publicly funded health care system, 
introducing new procedures that increase waiting times and decrease the 
number of patients seen by surgeons are politically difficult. Given this, 
participant 4 reflected that introducing oncoplastic surgery in Canada in a 
meaningful way is seen as 
“challenge, for sure. Anything that’s going to increase resources and 
decrease productivity is harder to swallow for sure, it means that you treat 
less patients.”  
 
Given the limited human resources available within the Canadian healthcare 
system, participant 3 speculated that oncoplastic procedures, if introduced, would 
be limited to procedures that are less the complex and require less operating 
time: 
“In the simpler ones, I think people will readily do just what I did, the 
mobilization of the breast tissue and use an extra layer of closure. That 
doesn’t take very long, but the pre-op planning and the extra… the more 
complex stuff probably adds an hour or so to your operating time. And that 
might be rate-limiting if you’re in a place where you have barely enough 
operating time to look after the pressure of cancer cases.” 
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While human resources may pose a significant barrier for surgeons located at 
academic hospitals, community practices were thought to be potentially enabling 
environments for oncoplastic surgery, depending of the local culture of the 
community hospital: 
“It might be easier for community general surgeons to accommodate a 
breast case that was a bit longer because they can trade, maybe do one 
less hernia on their list and devote that extra bit of O.R. time to the 
oncoplastic planning and that part of the procedure. That said a lot of 
people, who are doing a lot of breast cancer in the community, are under 
the same sort of pressure to use their O.R. time for cancer cases.” 
 
In contrast to the various human resource constraints identified above, the 
cosmetic benefits of oncoplastic surgery were described as being enabling for 
the adoption of the practice, because of the potential for the practice to minimize 
the costs associated with mastectomies. In this regard, participant 6 remarked 
that she is 
“hopeful that it actually will be a very good thing for the system because it 
would ideally minimize the amount of reconstruction that we need to do.” 
 
Participant 5 echoed this optimistic view and stated that he did not think that  
“oncoplasty would pose any significant problems for the Canadian health 
care system.” 
 
3.5.3 Courses 
While the mentorship intervention piloted in this study demonstrated a 
useful method for effectively and efficiently introducing new surgical techniques, 
participants reported a clear need for ongoing mentorship and training in the area 
of oncoplastic surgery. In the context of Canada, there is a distinct lack of training 
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opportunities and courses in the oncoplastic surgery. Moreover, the number of 
international courses that are offered in the specialty are limited, highly 
competitive, and require surgeons to take time off from their busy practices to 
travel to Europe or the United States. Several participants spoke about the 
challenges that they had faced accessing appropriate oncoplastic surgery 
courses. Participant 1, for example, stated: 
“The courses are very competitive and very difficult to get into because it 
is becoming an international gold standard and will, at some point. So, it’s 
quite competitive to get to and they’re very expensive, and it’s difficult to 
put your practice on hold and travel to attend these courses, but it’s 
absolutely worthwhile.”  
 
While participants generally described oncoplastic surgery courses as 
desirable learning opportunities, it was clear that the time and money required to 
attend them were often a significant barrier. Additionally, the usefulness of the 
courses was called into question, as it was acknowledged that the majority of 
courses available did not offer a hands-on component or wet lab; when wet-labs 
were incorporated, they often were not comprehensive enough to provide 
sufficient training: 
“And the other thing is simply that it’s costly and you only have a few 
opportunities a year to go to a meeting where you might be able to do a 
wet lab. I don’t really think the wet lab is enough to give you the 
confidence that you need; well, for me, anyway.” 
 
Mentorship and one-on-one training, like the intervention piloted in the 
study, were described by the surgeons as alternatives to courses, while being 
one of more effective ways to learn and implement new techniques. The lack of 
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opportunities to mentorship in this area, particularly for busy practicing surgeons, 
was lamented: 
“I think, it’s just learning how to do it, like most surgical procedures you 
learn it during your residency or fellowship. So, you watch somebody do it, 
you’re mentored through it, then you get to do it and you get to see the 
results. The barrier really is adopting or learning new techniques when 
you’re in practice where you’re not necessarily going to have that same 
opportunity. It would be great to go away and do a course or travel to 
another site. I think those are the best ways to learn it.  The challenge is 
finding time. Holding a meeting like we’re doing is I think the best to locally 
disseminate it but you’re not going to be able to get everybody because of 
our crazy schedules.” 
 
 
3.6 FUTURE OF ONCOPLASTIC SURGERY 
Despite the barriers to adoption, identified by the study participants, the 
findings suggest that surgeons are hopeful about the future of oncoplastic breast 
surgery in Canada. For some participants, the adoption of oncoplastic techniques 
was understood to be an inevitable outcome in the evolution of breast surgery 
practices. While participant 2 expressed hesitancy at the widespread acceptance 
of advanced oncoplastic techniques, they felt that basic oncoplastic techniques 
will be incorporated into general breast surgery in Canada in the coming years: 
“I think it will slowly percolate, and it will slowly become part of main 
surgical practice. Like all new techniques, they sort of take a while to be 
adopted, but they generally find their way into practice. I don’t think all of 
them; I think the most complex reconstructive techniques will only be done 
by a few, small, specially trained surgeons. Most of the basic techniques I 
think will easily be adopted. 
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Participant 1 was optimistic about the future of oncoplastic surgery and 
predicted that the techniques will become as prominent and ubiquitous in 
Canada as it is in Europe: 
“Ultimately, I think oncoplasty will become the standard of care in Canada.  
I think for level 1, it’s fairly already well accepted to do glandular closure, 
and that doesn’t take too much time, and so the Canadian system, there’s 
no big down side to that. I think the level 2 is challenging, because it takes 
a bit more time, and so there might be some resistance until finally patient 
demand makes it become the standard of care, when other patients hear 
about it, and then they won’t go to the people that have worse cosmetic 
outcomes. Then the level 3 is going to remain a problem because not 
every hospital and not every city has a plastic surgeon to do reductions 
with.” 
 
Given the numerous barriers identified in this study that hinder the uptake 
of oncoplastic surgery, participant 2 asserted that increased public and medical 
awareness of the benefits associated with the practice are integral for the wide-
spread adoption of practice: 
“Well, I think that as patients and other physicians, such as, the treating 
oncologists, as they become more aware of it and the benefits of it, the 
demand will come, and I think that really, it’s how it happened for 
reconstruction too. It wasn’t really until the patients and the political 
climate around it demanded that we provide that for patients, that’s when it 
really started to happen, and it will probably be the same. It would 
probably be women who recognize this is an important part of their care 
that will force the system to adapt to it.” 
 
 
 Thus, our results suggest that surgical mentorship was an effective way to 
introduce new surgical techniques to practicing surgeons. The results of the 
study demonstrate that mentorship increased surgeons’ knowledge of 
oncoplasty, their comfort and skill in performing new techniques, and their 
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perception of its benefits for their practice. This method was described as being 
preferable to formal learning opportunities and more accessible for busy 
clinicians. 
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CHAPTER 4. DISCUSSION 
 
Oncoplastic breast-conserving surgery is increasingly accepted as the 
standard of care for women with early-stage breast cancer across European 
countries. While oncoplastic techniques have been shown to produce better 
cosmetic outcomes than traditional surgical techniques without impacting 
oncological outcomes, the practice has not been widely integrated in Canada. 
Despite the mounting evidence that oncoplastic surgical (OPS) techniques 
reduce mastectomy and re-excision rates while producing a cosmetically superior 
result, Canada lags behind the rest of the international medical community in its 
uptake of oncoplastic surgery. Previous research has identified the lack of 
Canadian formal training opportunities for surgical residents and fellows as a 
significant factor contributing to the slow uptake of OPS (Maxwell, Roberts et al. 
2016).  OPS are currently not incorporated into Canadian general surgery 
residency curriculum and are not a formal component of Canadian surgical 
fellowship training for breast or oncology surgeons. The basic breast fellowship 
training in Canada consists of different rotations in breast surgical oncology, 
medical oncology, radiation oncology, breast imaging and pathology. During the 
fellowship, the trainees are exposed to different reconstruction techniques carried 
out by plastic surgery team during combined cases. As such, the trainees have 
no exposure to any OPS techniques during the standard breast fellowship 
program. 
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This study emerged out of an ablative and reconstructive breast surgery 
fellowship in 2013, at which time oncoplastic surgery was not routinely being 
used at London Health Sciences Centre and St. Joseph’s Healthcare Centre by 
the practicing breast cancer surgeons. While ablative and reconstructive breast 
surgery fellowships are intended to enable surgeons to develop expertise in the 
multidisciplinary management of breast disease, the fellows are not really 
exposed to OPS cases during their training. Given the standardization of OPS 
techniques globally, developing an OPS skill set is imperative for breast 
surgeons to provide excellent patient care. Acknowledging the specialized 
training is required in order to gain expertise in OPS. Given the paucity of formal 
educational opportunities in Canada, this study was designed to test the 
effectiveness and appropriateness of a six-week intra-operative surgical 
mentorship as a strategy for integrating OPS into already-established surgical 
practice. In addition to testing the effectiveness of inter-operative mentorship as 
an educational innovation, this study sought to identify and examine the barriers 
and opportunities for adopting OPS as a new technique at the University of 
Western Ontario. 
 
 
4.1 SUMMARY OF THE OUTCOME OF MENTORSHIP 
The participants’ perceptions of the intra-operative mentorship program 
implemented in this study and its effects on their surgical practice were described 
in Chapter 3. The results of the study suggest that surgical mentorship is an 
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efficient way to introduce new techniques to practicing surgeons that facilitates 
their adoption into their routine surgical practice. This model of surgical 
mentorship is broadly applicable, and can be used widely throughout the surgical 
community to support the introduction of various innovative techniques. Such an 
approach enhances the utilization of the expertise within the field, and 
encourages local surgeons pioneering novel techniques to share their 
experiences with those willing to learn. In addition, mentoring provides a way to 
overcome the unnecessary burdens (both financial and in terms of the time 
commitment required) associated with travel to attend a hands-on course at 
another location. The burdens were identified by participants as significant 
barriers to accessing formal OPS educational opportunities. In contrast to formal 
courses, the surgeons who participated in this study described inter-operative 
mentorship as an accessible, flexible and affordable educational opportunity that 
supported their ability to develop new expertise.  
Furthermore, in combining pre-operative planning with intra-operative 
discussion and application, the hybrid approach of the mentorship program 
enabled participants to achieve their learning objectives. The surgeons reported 
that this method was superior to self-study and other formal courses (with or 
without a wet lab). The efficacy of the mentorship program was highly visible in 
the post-intervention interviews, in which most surgeons described how they had 
incorporated different levels of oncoplastic techniques into their standard 
practice. The increasing awareness of OPS and its benefits are also visible at the 
intuitional level, as oncoplastics has recently become a part of the formal 
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fellowship training at London Health Sciences Centre (LHSC) and St. Joseph’s 
Healthcare Centre (SJHC) in London, Ontario. These changes to fellowship 
training, in part, are a response to the diffusion of the surgical innovation piloted 
in this study.  
There are indications that the broader landscape of OPS is changing 
across Ontario. Recently, an oncoplastic partnership program was introduced by 
academic and community surgeons in Ontario, who are considered local experts 
in the emerging Canadian field. The surgeons initiated a hands-on oncoplastic 
surgery course, offered several times a year, with locations in Toronto, Ottawa 
and London. Additionally, oncoplastic breast rounds were created by the same 
group; these are now offered on a monthly basis, via teleconferencing, to all the 
hospitals in Ontario. 
To support the integration of OPS into breast surgical practices in Ontario, 
it is imperative to foster good relationships between the plastic surgeons and 
general breast surgeons. Oncoplastic surgery requires an immense amount of 
collaboration between plastic and breast oncology surgeons, in order to plan the 
proper therapeutic approach and to achieve the best possible surgical outcome 
for the patient. Collaboration between these surgical sub-specialties is of vital 
importance.  
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4.2 DIFFUSION OF INNOVATION 
As described in Chapter 2, the design of this study was informed by 
Rogers’ theory of Diffusion of Innovation (Rogers 1983). This conceptual 
framework enables in-depth exploration of the multiple factors that affect, shape 
or impede the adoption of new clinical behaviours and techniques. OPS as a 
surgical innovation is described here, evaluating its success in relation to the four 
elements affecting diffusion identified by Rogers.  
While oncoplastic surgery is a well-established practice in other areas of 
the world, especially in Europe, it is still considered an innovation in the 
Canadian healthcare system (Khayat, Brackstone et al. 2017).  In 2013, intra-
operative mentorship training was introduced at LHSC and SJHC to provide 
practicing breast surgeons with an opportunity to gain expertise in OPS 
techniques. The surgeons who participated in the mentorship program reported a 
more favourable perception of OPS and increased knowledge of its advantages 
for their breast practices. In the period following the intervention, participants 
indicated that they had incorporated OPS into their practices and could provide 
patients, who would otherwise be offered a mastectomy, with new breast-
conserving options. Interestingly, some surgeons also commented that the 
integration of oncoplastic surgical techniques increased their surgical 
satisfaction. 
According to Rogers, there are five crucial elements that affect the 
adoption of surgical innovations: relative advantage, compatibility, complexity, 
trialability and observability. 
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4.2.1 Relative Advantage 
Rogers described the ‘relative advantage’ of an innovation as the degree 
to which it is perceived to be superior to the current practice. There is a 
considerable body of research that demonstrates the advantages of OPS, 
particularly with regards to the cosmetic outcome. While all participants reported 
having some knowledge of OPS prior to the mentorship intervention, many were 
unable to describe the benefits of such techniques for patients clearly. After the 
completion of intra-operative mentorship, several participants reported offering 
oncoplastic surgery to selected patients who would otherwise need a 
mastectomy, and reflected that the outcome of these cases was optimal. These 
findings indicate that the mentorship program enabled participants to understand 
the ‘relative advantage’ of OPS better, assisting with integration of the techniques 
into their practice. 
 
1.4.2 Compatibility 
‘Compatibility’ is a measure that refers to the degree to which a new 
surgical technique is viewed as being reconcilable or consistent with current 
values, practices, and the needs of potential adopters. Rogers argued that 
innovations that address current issues or problems identified by clinicians have 
an increased probability of adoption. As described in Chapter 3, many practicing 
breast surgeons and their patients are satisfied with current surgical techniques. 
This hinders the adoption of OPS, as currently there is not a widespread 
surgeon-identified need for technical innovation. However, the results of this 
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study suggest that intra-operative mentorship may be an effective technique to 
communicate the compatibility of OPS with the current standard in the treatment 
of breast cancer, and highlight the ways in which these techniques address 
previously unacknowledged unmet needs. 
 
1.4.3 Complexity 
The complexity of new surgical techniques and the level of skill required to 
adopt them affect their diffusion effectivity. Techniques that are perceived to be 
difficult to understand and onerous to learn are less likely to be adopted, 
particularly without addressing a clear and pressing unmet need. Oncoplastic 
surgical techniques are divided into three levels according to the extent of 
training and skill that are required to perform each technique. At present, the 
amount of training required for competency in each skill level has not yet been 
standardized. The results of this study suggest that a six-week mentorship period 
may provide sufficient training for surgeons to perform level 1 and 2 procedures, 
while level 3 procedures may require additional training. 
 
1.4.4 Trialability 
Rogers described ‘trialability’ as the degree to which the surgical 
innovation is amenable to trial and modification. Innovations that can be 
appraised on a trial basis are more likely to be adopted because it affords 
clinicians the opportunity to assess the feasibility of the procedures, its 
acceptability to patients, and the potential outcomes before committing to its full 
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adoption. The collaborative nature of the mentorship program provided the 
participants with the opportunity to observe, test out and assess the post-surgical 
outcomes of OPS without having to commit themselves to extensive or 
expensive formal training. Their exposure to a variety of techniques enabled the 
surgeons to ‘trial’ a variety of OPS procedures with a range of different patients, 
and to assess which techniques they would like to adopt and practice, and what 
techniques they would omit and never use. Thus, surgical mentorship may 
provide an ideal opportunity to practicing surgeons to ‘trial’ new techniques 
without committing extensive resources to formal training or courses. 
 
4.2.5 Observability 
Rogers defined ‘observability’ as the degree to which the superior 
outcome of the innovation can be readily perceived by other clinicians and 
patients. The more ‘visible’ the favourable results are, the more discussion is 
stimulated between clinicians and the more knowledge about the innovation 
circulates among communities of practice. Highly observable outcomes facilitate 
the adoption of new surgical techniques. As an innovation, oncoplastic surgery is 
hindered by the fact that the final cosmetic outcome is not visible until after the 
patient has completed radiation therapy. However, the preliminary results of the 
surgical technique were described by participants as being promising. The 
extensive length of time between surgery and final result are not conducive for 
facilitating rapid adoption of the practice, but over time, as the superior cosmetic 
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results of this practice reveal themselves, the ‘observability’ of the innovation 
may improve.  
 
 
4.3 COMMUNICATION CHANNEL 
The channels, or modes by which information about new clinical 
techniques is communicated, influence its diffusion. Face-to-face exchange of 
information has been shown to be an effective and persuasive communication 
strategy as it provides the opportunity for knowledge to be tailored to the 
recipient and their specific clinical context (Bero, Grilli et al. 1998). Moreover, this 
mode of communication is particularly effective in instances where there is a high 
degree of professional resemblance between individual introducing the 
innovation and the recipient of the knowledge (Bero, Grilli et al. 1998). The 
results of our study support this claim, as the surgical mentorship was well 
received by the participants of our study. As described in Chapter 3, the 
surgeons report that the presence of a skilled surgical mentor facilitated their 
learning and increased their comfort experimenting with OPS techniques.  
 
 
4.4 SOCIAL SYSTEM 
For any surgical innovation to be adopted, there has to be a harmony and 
smooth transition within the social system involved in the adoption of this 
innovation. In our study, there was an active collaboration between breast 
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oncology surgeons and plastic surgery team; these surgical sub-specialties are 
the cornerstone in the adoption of oncoplastic techniques. The high-degree of 
teamwork at LHSC and SJHC facilitated the smooth transition and the 
acceptance of oncoplastic surgery as an alternative to the previous practice. 
Excellent communication and advanced planning through a pre-set agreement 
between both groups enabled the smooth integration of the techniques into 
surgical practice.  
When examined through the conceptual framework of diffusion of 
innovation, the results of our study are promising. The intra-surgical mentorship 
program piloted in this study improved the participants’ perceptions of OPS 
across the five elements. In particular, the program improved the participants’ 
knowledge of the relative advantages of OPS, demonstrated the compatibility of 
the techniques with current practices, provided an opportunity for surgeons to 
implement and assess the techniques, and made visible the superior cosmetic 
outcomes of the procedures.  
The theory of surgical innovation has been used by several other scholars 
to describe and predict the diffusion of surgical innovations Many examples exist 
in the history of surgical innovation, where the same theory was used and 
applied successfully to adopt new innovations (McMasters, Wong et al. 2001, 
Simunovic, Coates et al. 2013, RoyalCollegeofSurgeonsofEngland 2018). The 
best example is the adoption of sentinel lymph node biopsy (SLNB), where it 
came to replace the standard of full axillary dissection for regional staging in 
every patient with breast cancer (McMasters, Wong et al. 2001): originally, SLNB 
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as a technique was rejected by many surgeons in England, since they did not 
think it would improve the outcomes. However, a few surgeons opted to test this 
different approach, demonstrating that with the adoption of proper training 
methods, SLNB could be done as a day surgery, thus reducing the cost, and 
eliminating the financial barrier to adoption. Although the lack of infrastructure 
within the nuclear medicine was initially a factor, the surgeons were able to 
overcome this. As a result, when the new guidelines for axillae treatment in 
England were issued, SLNB was added as a standard. Other successful example 
is the introduction of laparoscopic colorectal surgery and robotic-assisted radical 
prostatectomy in the UK (RoyalCollegeofSurgeonsofEngland 2018). 
Another example where the same theory was used is the Cluster-
Randomized Quality Initiative in Rectal Cancer (QIRC) Trial (Simunovic, Coates 
et al. 2013): the new, total mesorectal excision technique was found to be 
superior to that of the previously-used standard, resulting in similar rates of 
adoption between early and late adopters. This occurred despite the fact that the 
late adopters were still satisfied with the outcomes obtained by the use of 
traditional technique. As such, our study shows some similarities to the above, 
since participating surgeons identified self-satisfaction of their surgical outcomes 
as a barrier to the adoption of new techniques. 
Comparison of the early versus late adopters in the QIRC study found no 
differences among the surgeons’ median year of graduation, availability and 
interest in attendance at meetings (either local or international), resource 
availability, interest and willingness to learn and adopt new techniques, or their 
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positive attitude towards their surgical community. As such, these findings were 
very similar to those of our study, in terms of our participant characteristics. 
 
 
4.5 BARRIERS TO OVERCOME 
This study identified several barriers to the acceptance of oncoplastic 
surgical techniques in London, Ontario. The first and most unexpected barrier 
was the degree of surgeon satisfaction with the cosmetic and oncological 
outcome of current surgical procedures. This poses a significant barrier to the 
adoption of OPS techniques because it indicates a low degree of ‘compatibility’ 
and ‘relative advantage’ of the practice. In part, the problem is a product of the 
lack of feedback from patients regarding the satisfaction with the cosmetic 
outcome of their breast surgeries. Feedback from patients is hindered by both 
the long recovery period and the overwhelming experience of breast cancer. 
Given these factors, cosmetic outcome is often not at the forefront of patients’ 
minds. Unfortunately, there is no good formal method of evaluating the patient-
surgeon satisfaction with the surgical outcome, due to the disparity in the 
definitions of ‘success’ by the surgeon versus that of the patient (Jagsi, Li et al. 
2015). 
Currently, novel assessment tools are being developed to address the 
evaluation that would include cosmetic outcome. For example, the BREAST-Q 
module, developed by the Memorial Sloan-Kettering Institute for Cancer 
Research (qportfolio.org), is designed to provide essential information about the 
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impact and effectiveness of breast surgery via the patient-reported outcome 
measure (PROM). This promising module can now be applied to validate the 
effectiveness of the outcomes of oncoplastic surgeries in comparison to the 
traditional oncological procedures. This tool holds great potential for assisting the 
diffusion of OPS because it spreads knowledge about procedure and its 
outcomes. It may raise patients’ awareness about the availability of OPS surgical 
procedures and facilitate the adoption of oncoplastic techniques by breast 
surgeons. 
One of the most critical barriers to the adoption of oncoplastic surgery into 
routine surgical practice is the lack of available and easily accessible training that 
include the real patient case scenarios. Given the complexity of OPS, this type of 
training is necessary for the integration of new surgical techniques into practice. 
In order to overcome this barrier, the emerging oncoplastic partnership in Ontario 
needs to be supported by Health Canada and the Royal College of Physicians 
and Surgeons in their continuing efforts to offer regular hands-on training in 
various locations within the country. 
In particular, the lack of formal training during surgical residency and 
fellowship pose another significant barrier. As mentioned by one of the study 
participants, current breast fellowships do not offer trainees any exposure to 
oncoplastic procedures, despite the fact that trainees desire this type of training.  
To overcome this, oncoplastic surgery should be incorporated during surgical 
fellowship training, and general surgery residents should be exposed to basic 
level 1 procedures during their formal training. As oncoplastic surgery 
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increasingly becomes the standard of care replacing the traditional lumpectomy 
procedures, it is of vital importance that surgical trainees develop competencies 
in these techniques. In response to this need, the University of Western Ontario, 
in collaboration with the University of Ottawa, has started a 1 to 2-year 
oncoplastic breast surgery fellowship, tailored to the educational needs of the 
fellows and the existing program requirements. 
The final barrier to adoption of any new surgical techniques is the 
acceptance by the Canadian healthcare system. The oncological and cosmetic 
advantages of oncoplastic surgery need to be explicitly communicated, to 
encourage its uptake and overcome resistance within the healthcare system. To 
advance its adoption, the benefits of oncoplastic surgery must clearly address 
both the issue of patient satisfaction with the cosmetic outcome and the cost-
effectiveness of the procedures employed. One possible solution to this problem 
is the formation of a Canada-wide oncoplastic surgery case registry (or, to begin 
with, even just a provincial or local registry); every surgeon would report his/her 
cases, including all complications and utilization of the operating room time. The 
registry would allow for objective feedback and a robust cost-benefit analysis. 
Given that Canada lags behind (in comparison to other leading countries) in the 
field, access to the registry might also facilitate the number of pertinent 
publications in the field of breast cancer surgery. 
While there is an excellent working relationship between plastic and breast 
oncology surgeons at our institution (i.e. LHSC/SJHC), this relationship may not 
exist at other institutions or community hospitals. The experience from our 
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mentorship program may offer an insight into how to bring the two teams 
together and foster collaboration between the groups. Drawing on our 
experience, we suggest the following guidelines to promote collaborative working 
relationships: level 1 oncoplastic surgical planning and the actual oncoplastic 
surgical excision procedure should be performed by the oncology surgeon; level 
2 oncoplastic surgical planning and the actual oncoplastic surgical excision 
procedure should also be done by the oncology surgeons, except when the need 
for symmetrization arises, in which case plastic surgery expertise is required; and 
level 3 oncoplastic surgery procedures should be planned by the plastic 
surgeons: the oncology surgeon should do the procedures on the diseased 
breast as planned by the plastics team, with the plastics working simultaneously 
to symmetrize the contralateral side. We found that following these guidelines will 
provide for a smooth transition to the adoption of oncoplastic techniques in any 
community. 
 
 
4.6 STUDY LIMITATIONS 
While the outcome of our study looks promising, the study evaluated the 
role of mentorship in adopting oncoplastics only at the institutions in one city: that 
of LHSC and SJHC in London, Ontario. The outcomes may differ at other 
institutions, or within smaller community hospitals. 
Cost-benefit analysis of oncoplastic surgery was not performed. In order to 
evaluate the effectiveness of oncoplastic surgery, a thorough assessment of all 
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variables must be undertaken. Although the benefit of oncoplastic techniques to 
the patient outcomes cannot be refuted, the additional increase in procedure time 
versus long-term benefits (e.g. shortened disability period, improved rate of 
return to workforce) must also be weighed. 
In terms of sample size, our study consisted of six surgeons. This was a 
sample of convenience. Although thematic saturation was reached in the study, 
the small participant group size can also be considered as a study limitation. 
Long-term outcome of the mentorship in our study cannot be assessed, 
given the timeframe and the scope of the program. As such, an additional study, 
of a different design would be required to evaluate the long-term effects and 
acceptance of oncoplastic surgery by practicing surgeons. 
The final limitation of the study was the length of the intervention. The 
mentorship took place over six weeks, which was considered not enough by 
some of the surgeons involved in the study. This was mainly due to the wide 
range of techniques and the need for case per case judgment, which may not be 
easy to cover within this period. The surgeon may need to wait for many clinic 
visits to find a suitable patient for specific procedure. 
 
 
4.4 FUTURE DIRECTIONS 
 To facilitate better awareness and acceptance of oncoplastic surgery into 
the routine breast cancer surgical practice, feedback from both the patient and 
the surgeon reporting on the satisfaction with the outcome should be obtained. 
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This can be implemented by using the patient satisfaction tools already employed 
in the United States. 
 To adopt the techniques of oncoplastic surgery into routine surgical 
practice, the breast cancer surgery residency and fellowship curricula need to be 
updated, to include training in the methodology. Mentorship programs can be of 
great value, and can also be applied to other institutions or settings. 
 It would be of great benefit to create a nationwide oncoplastic surgery 
registry, providing better visibility of these novel surgical procedures. The registry 
could be modelled on the one available in the United States; it would not only 
allow for the evaluation of the surgical outcomes, but also offer an additional 
research tool into various modern surgical approaches. 
 Finally, in order to include oncoplastic surgery within the standard 
Canadian healthcare system, a thorough cost-benefit analysis must be 
performed. The analysis must not only demonstrate that oncoplastic techniques 
and procedures do not dramatically increase the cost of patient care, but they 
provide for a significantly better patient outcome (with much less disability), 
perhaps even saving money in the long term. Finally, it needs to be conveyed to 
the administration that out of all advanced countries in the world, Canada really 
lags behind in the field, given that oncoplastic surgery is now considered a 
standard of care elsewhere in the world. 
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APPENDIX II. LETTER OF INFORMATION: CONSENT TO PARTICIPATE IN A 
RESEARCH STUDY 
 
Principal Investigator: 
Dr. Muriel Brackstone, MD, PhD, FRCSC 
Tel: 519 685 8712 
Muriel.Brackstone@lhsc.on.ca 
 
 
INFORMED CONSENT TO PARTICIPATE IN A RESEARCH STUDY	
 
Full Study Title: When Student Becomes Teacher: Does Implementation of a 
Breast Surgery Fellowship Improve Knowledge Dissemination Amongst Surgical 
Staff? 
 
Principal Investigator: Dr. Muriel Brackstone, Surgical Oncologist 
_______________________________________________________________ 
 
INTRODUCTION 
 
This study will identify a novel technique in breast surgical oncology (oncoplastic 
breast conservation). The educating clinical fellow in the Ablative and 
Reconstructive Breast Surgery program has been trained through the American 
Society of Breast Surgeons Annual Oncoplastic Course. As an attending staff, 
you will be asked to rate your use of the specific technique, as well as your 
comfort level and understanding pre- and post-exposure to the educated clinical 
fellow.  
 
You will also be asked to participate in an open-ended interview where you will 
be asked to outline your understanding of these procedures and your perceived 
barriers to implementation of these techniques. Exposure to these procedures 
will include having the fellows pre-screen the operative lists and suggest 
oncoplastic procedures to each staff surgeon for each patient periodically over a 
one to three month period. Afterwards, you will undergo a debriefing open-ended 
interview where you will be asked to outline your comfort with these procedures, 
the likelihood that you will use them independently in the future, and any barriers 
to ongoing use of oncoplastic surgery where indicated. 
 
This study aims to determine the level of knowledge dissemination from fellow to 
attending surgeon in a clinical fellowship setting. 
 
As a general surgeon performing breast surgery at Western University, we value 
your opinion on this matter and ask for your participation in our research. Your 
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participation in this study is completely voluntary and may be withdrawn at any 
time. Take the time you need to read over and fully understand this information 
prior to completing the consent form. Feel free to discuss this information and 
participation in this study with anyone you wish or contact us for additional 
information. 	
 
PURPOSE 
 
Knowledge translation (KT) is a “dynamic and iterative process that includes the 
synthesis, dissemination, exchange, and ethically sound application of 
knowledge to improve the health of patients, provide more effective health 
services and products, and strengthen health care systems”. Many methods of 
KT exist, including continuing medical education, clinical practice guidelines and 
systematic reviews, audit, feedback, and reminders, educational outreach, 
reward and punishment programs, and operative demonstrations. Previous 
studies have demonstrated that the majority of the above methods have done 
little to change physician practice. This has led to the conclusion that physicians 
are reluctant to change their practice, and that improved KT interventions are 
necessary. 
 
An exhaustive search of the literature fails to identify any studies examining the 
effect of clinical fellowship implementation on knowledge translation to attending 
staff. As more general surgery graduates choose to pursue additional fellowship 
training, studies have consistently demonstrated improved patient outcomes in 
centres with affiliated fellowship programs. Furthermore, clinical fellowship 
programs have not been shown to compromise resident experience. Western 
University has trained breast surgery fellows intermittently and informally over the 
past 7 years; however, 2016 will mark the first year of a formal breast ablative 
and reconstructive surgery fellowship. Fellowship goals and objectives have 
been developed in accordance to the CanMEDS roles and fellows will be formally 
evaluated for the first time. 	
 
This study aims to examine the dissemination of surgical knowledge from clinical 
fellow to attending staff, as well as the trickle down effect from staff to general 
surgery residents in the setting of a new formal breast surgery fellowship. In 
order to assess this phenomenon, clinical fellows will first pursue course-based 
training in oncoplastic breast surgery. Oncoplastic breast surgery is the 
combination of oncologic breast conservation with volume displacement 
techniques. Its goal is complete removal of the lesion with clear margins and 
excellent cosmesis, while performing a single definitive operative procedure. This 
approach has gained wide acceptance in Europe, but is less utilized in North 
America, despite studies that have demonstrated the oncologic safety of this 
technique. 
 
Attending surgeons’ use of oncoplastic techniques, as well as their perceived 
understanding and comfort level with these techniques, will be assessed pre- and 
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post- clinical fellow education. This will include an open-ended interview with Dr. 
Eman Khayat, a breast oncology fellow, following her training and 3 month 
exposure period where she will pre-screen each operative list and propose 
oncoplastic techniques for each of these patients. This will allow for an 
examination of the uptake of new knowledge from clinical fellow to attending 
surgeon. Beyond this, general surgery residents on their breast oncology rotation 
will also be surveyed on the use of these techniques in the operating room and 
the oncoplastic specific teaching in order to determine if the new knowledge 
trickles down to resident education. Furthermore, the longevity of knowledge 
uptake will be assessed by surveying attending surgeons at six months and one 
year from initial exposure. This will allow us to determine if the oncoplastic 
techniques taught by the clinical fellow are still in use and provide a measure of 
project impact. 
 
RESEARCH INTERVENTION 
 
Participation in this study will involve completion of pre- and post-exposure 
surveys, as well as three and six month follow-up surveys. It will also involve two 
audio-recorded one-on-one interviews. Surveys will be available online via 
SurveyMonkey. Participants will receive invitation e-mails for survey completion 
and can be completed at your convenience. Each survey should take no more 
than ten minutes. Each interview should take no more than 30 minutes and will 
be conducted at the breast care centre at a date and time convenient for you. All 
surveys and interviews must be completed in order to complete this study.	
 
PARTICIPANT SELECTION 
 
You have been invited to participate in this research because you are an 
attending general surgeon practicing breast surgical oncology at Western 
University. We believe that your experience in this field and opinion on this 
matter can help us understand the patterns of knowledge translation in the 
setting of a breast surgery fellowship. Approximately 25-30 physicians will 
participate in this study. 
 
PARTICIPATION 
 
Your participation in this study is completely voluntary. You may withdraw from 
this study at any time with no consequences. Your decision will have no effect on 
employment or salary. You have the right to request the withdrawal of your data 
from the study at any time. 
 
RISKS 
 
The risks associated with breast of confidentiality for the attending staff are 
minimal. They include questions related to surgeon practice in comparison to 
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colleagues (i.e., use or non-use of oncoplastic techniques) and potential 
embarrassment. 
 
BENEFITS 
 
There is no remuneration associated with participation in this study. There are no 
direct benefits; however, participation in this study will help to determine the 
patterns of knowledge dissemination associated with implementation of a formal 
breast surgery fellowship program. This in turn will contribute to the Canadian 
surgical education data and may aid in the future development of breast surgical 
oncology training programs and oncoplastic surgery teaching across the 
province. 
 
ALTERNATIVES 
 
You may choose not to participate in this study. Your choice will have no effect 
on your employment, salary, academic standing, or evaluations. 
 
CONFIDENTIALITY 
 
We will not be sharing information about you to anyone outside of the research 
team. Data will be collected in a fashion that precludes identification of subjects 
directly. Study data will be de-identified upon collection. Each response will be 
assigned a unique sequential ID number. No other identifying data will be 
included in the response. One master log will exist that correlates the participant 
name to the sequential ID number. This log will be kept and stored separately 
from the data. All data will be password protected and kept for a minimum of 15 
years, after which it will be destroyed according to Western University policy. 
Access to all records and data will be limited to authorized persons. The UWO 
Health Sciences Research Ethics Board may require access to study records for 
quality assurance and auditing purposes. 
 
No identifying information will be used in publications or presentations of the 
results of this study. 
 
COSTS 
 
There will be no cost to you to participate in this research study. 
 
PARTICIPANT RIGHTS 
 
By completing this survey, you do not give up any of your legal rights against the 
investigators, sponsor, or involved institutions for compensation, nor does this 
form relieve the investigators, sponsor, or involved institutions of their legal and 
professional responsibilities. 
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CONFLICTS OF INTEREST 	
 
None to declare. 
 
 
COMMERCIALIZATION 
 
None. 
 
SPONSOR/SUPPLIER 
 
N/A 
 
QUESTIONS ABOUT THE RESEARCH STUDY	
 
Please contact Dr. Eman Khayat, MD if you have any questions about this study. 
 
Eman Khayat, MD 
Breast Surgical Oncology Program 
London Regional Cancer Program 
790 Commissioners Road East, Office A3-931 
London, Ontario  N6A 4L6 
Tel:  
E-mail:  
 
  
	 145 
APPENDIX III. PERMISSIONS TO USE COPYRIGHTED MATERIALS 
 
III.1 British Journal of Surgery 2012; 99(10): 1389-95. 
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APPENDIX IV.  THEMES IDENTIFIED DURING THEMATIC ANALYSIS OF 
QUALITATIVE DATA 
 
IV.1 Pre-Intervention 
(1) Perception of Oncoplastic Surgery by Practicing Surgeons 
These were the perceived ideas defining how much the participating 
surgeons generally knew about the term ‘oncoplastic surgery’ and what it entails. 
 
(2) Knowledge of Oncoplastic Surgery 
This was defined as the knowledge of technical details the participating 
surgeons had about oncoplastic surgery. 
 
(3) Opinion of Practicing Surgeons about Oncoplastic Surgery 
The initial opinion of the participating surgeons was explored about 
oncoplastic breast surgery, as reflected by their general knowledge and 
perceived ideas. 
 
 
IV.2 Mentorship 
(1) Pre-Intervention 
The surgeons’ opinions about different methods of adopting new 
techniques and their incorporation into practice were gathered. Mentorship was 
highlighted as the main purpose of the study.  
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(2) Post-Intervention 
The feedback from the participating surgeons about the period of 
mentorship, as well as its validity in facilitating the adoption of new techniques 
was outlined. 
 
 
IV.3 Post-Intervention 
(1) Knowledge  
  The participating surgeons’ knowledge of oncoplastic surgery after the 
mentorship intervention was evaluated. 
 
(2) Opinion 
The opinion of oncoplastic surgery after the intervention was expressed. 
 
(3) Effect 
The effect of the mentorship program in the participating surgeon’s future 
practice was assessed. 
 
 
IV.4 Working with Plastics Surgical Team 
The relationship between the participating general surgeons and plastic 
surgery team, as well as its effect on the process of adopting oncoplastic surgery 
was explored. 
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IV.5 Barriers to Adoption of Oncoplastic Surgery 
The following barriers were identified by the participating surgeons: 
(1) Surgeon’s self-satisfaction; 
(2) Lack of availability of formal training or accessible courses; 
(3) The Canadian Healthcare System, in the context for the adoption. 
 
 
IV.6 Future of Oncoplastic Surgery 
(1) Increase surgeons’/patients’ awareness; 
(2) Collaboration between teams; 
(3) Feedback. 
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APPENDIX V. CODES GENERATED DURING THEMATIC ANALYSIS OF 
QUALITATIVE DATA 
 
The following codes were identified in thematic analysis of qualitative data: 
1. Background 
2. Training 
3. Practice 
4. Collaboration or relation between plastic and general surgery 
5. Discussion 
6. The interest in breast surgery  
7. Popularity 
8. Training 
9. Techniques 
10. Judgment 
11. Barriers 
12. Practice 
13. Advanced techniques 
14. Oncoplastic surgery 
15. Cosmesis 
16. Opinion on cosmesis 
17. Outcome 
18. Procedure 
19. Time 
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20. Fellowship 
21. Reasoning 
22. Fellows 
23. Mentorship 
24. Experience 
25. Adoption 
26. Learning from fellows 
27. Difficulties 
28. Cultural barriers 
29. Lack of knowledge 
30. Sexual discrimination 
31. Prospective about the procedure 
32. Level of comfort 
33. Patient selection 
34. Quality of courses. 
35. Fellows and spread of knowledge 
36. Instituting effect in spreading the knowledge 
37. Limitations of learning 
38. Belief in the technique 
39. Fellow character can affect learning 
40. Needs imagination 
41. Extra time 
42. Central breast centres 
	 152 
43. Oncological priority 
44. Low interest in reconstruction 
45. Barriers to adopt oncoplasty 
46. Spectrum of oncoplastic surgery 
47. Plastic restriction 
48. Plastic opinion 
49. Availability of fellows 
50. Mentorship 
51. Importance of fellowship 
52. Fellows as a source of knowledge 
53. More subspecialized 
54. Changing spectrum of breast surgery 
55. Limited access to hands-on 
56. Good acceptance for learning 
57. International courses 
58. Traditional ways of learning 
59. Difficult techniques with no experience – need more training 
60. Methods of learning 
61. Level of confidence related to the level of experience 
62. Senior restriction  
63. Extra training in Europe 
64. Information on training 
65. Good oncological outcome 
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66. Recent change in practice 
67. Superior result in first surgery 
68. Plastic team interest 
69. Good collaboration, limited availability 
70. Different sources of referral to plastic surgeons 
71. Late complaints about cosmesis 
72. Surgeons mention cosmesis to patients. 
73. Patient satisfaction 
74. Patients overwhelmed with cancer 
75. Opinion of cosmesis in first visit 
76. Options for defects correction 
77. Factors affecting patient’s decision 
78. Discuss scar pre-op 
79. Post-op cosmetic problem 
80. Anatomical discussion with radiologist 
81. Radiologist and surgical planning 
82. Getting second opinion 
83. Opportunity to discuss reconstruction 
84. Multiple visits 
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